STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 175976

TO: Tamthom Truong
Location: REM/5B19/5C18
Art Unit: 1624
Friday, January 20, 2006
Case Serial Number: 10/821906

From: John DiNatale
Location: Biotech-Chem Library
REM-1B65
Phone: (571)272-2557

john.dinatale@uspto.gov

Search Notes

Examiner Truong,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

John DiNatale
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2557

STIC Scientific & Technical Information Center

SERVICES

Database Search	submit
PLUS Search	submit
Book/Article Delivery	submit
Book/Journal Purchase	submit
Foreign Patents	submit
Telework Support	
Translation	submit
SIRA Automation Training	
STIC Demos & Events	

RESOURCES

STIC Online Catalog	
Databases	
E-Books	search
E-Journals	search
Legal Tools	
Nanotechnology	
Reference Tools	

STIC

About Us
FAQ
Locations & Hours
News
Site Map
Staff

Search STIC Site

GO

Online Database Search Form

Search requests relating to published applications, patent families, and litigation can t form and clicking on "Send."

Tech Center:

(•) TC 1600 ( ) TC 1700 ( ) TC 2100 ( ) TC 2600 ( ) TC 2800
( ) TC 2900 ( ) TC 3600 ( ) TC 3700 ( ) Law Lib ( ) Other

2 m. amdt.

Your Contact Information:

* indicates mandatory information.

Your Name: TAMTHOM N. TRUONG
*Email Address: tamthom.ngo@yahoo.co
(e.g., Susan.Smith@uspto.gov)
*Employee No.: 74142
*Art Unit/Org.: 1624
*Office Location: REM - 5B19
*Phone No.: x 20676
Mailbox No.: REM - 5C18

***Case serial number:** 10/821,906
If not related to a patent application, please enter NA here.

Class / Subclass(es) 514/266.2, 266.4; 544/ 284, 293

Earliest Priority Filing Date: 4-9-2003

Format preferred for results:
[x] Paper [ ] Diskette [ ] E-mail

Query attached

Provide detailed information on your search topic:

- In your own words, describe in detail the concepts or subjects you want us to se
- Include synonyms, keywords, and acronyms. Define terms that have special me
- *For Chemical Structure Searches Only*
  Include the elected species or structures, keywords, synonyms, acronyms, and
- *For Sequence Searches Only*
  Include all pertinent information (parent, child, divisional, or issued patent numb
  serial number.
- *For Foreign Patent Family Searches Only*
  Include the country name and patent number.

10/821,906

Query

① Process of making formula I



(I) (2) (3)

R^3 = $-(CR'R^2)_{0-6}$—(4-10 membered Heterocyclic group)

R^{13} + R^{14} = each is H, C_1-C_6 alkyl or CH_2OH

R^{19} + R^{20} = each is $-(CR^{15}R^{16})_{0-6}-OR^{17}$ or OR^{18}

See attached Claim 1 for defs of R^1, R^2, R^{15}, R^{16}, R^{17} + R^{18}.

X = halogen

② Process of (making) or converting formula I to formula 5 by:



(4) (5)

See attached Claim 1 for defs. of R^3, R^{13}, R^{14}, R^{15}, R^{16} + R^{17}.

Also see attached Claims 1, 24, 26 for any additional information.

IN THE CLAIMS:

Please amend claims 1 and 19 without prejudice, as follows:

1. (Currently Amended) A method for preparing a compound of formula 1



1

acceptable salts, and solvates thereof, wherein:

k is an integer from 1 to 3;

m is an integer from 0 to 3;

p is an integer from 0 to 4;

R^1, R^2, R^4, and R^5 are each independently selected from H and C_1-C_8 alkyl;

R^3 is -$(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, said heterocyclic group is optionally fused to a benzene ring or a C_5-C_8 cycloalkyl group, the -$(CR^1R^2)_t$- moiety of the foregoing R^3 group optionally includes a carbon-carbon double or triple bond when t is an integer between 2 and 5, and the foregoing R^3 group, including any optional fused ring referred to above, is optionally substituted by 1 to 5 R^{10} groups;

each R^6 is independently selected from halo, hydroxy, -NR^1R^2, C_1-C_8 alkyl, trifluoromethyl, C_1-C_8 alkoxy, trifluoromethoxy, -$NR^7C(O)R^1$, -$C(O)NR^7R^9$, -$SO_2NR^7R^9$, -$NR^7C(O)NR^9R^1$, and –$NR^7C(O)OR^9$;

each R^7, R^8 and R^9 is independently selected from H, C_1-C_6 alkyl, -$(CR^1R^2)_t$(C_6-C_{10} aryl), and -$(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R^7, R^8 and R^9 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR^1R^2, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, hydroxy, and C_1-C_6 alkoxy;

or each R^7 and R^9, or R^8 and R^9, when attached to the same a nitrogen atom, can be taken together to form a 4 to 10 membered heterocyclic ring which may include 1 to 3 additional hetero moieties, in addition to the nitrogen to which said R^7, R^8, and R^9 are attached, selected from N, N(R^1), O, and S, provided two O atoms, two S atoms or an O and S atom are not attached directly to each other;

each R^{10} is independently selected from oxo (=O), halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -$C(O)R^7$,

$-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-NR^7SO_2NR^9R^1$, $-NR^7C(O)NR^1R^9$, $-NR^7C(O)OR^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, $-SO_2NR^7R^9$, $-S(O)_j(C_1-C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_qC(O)(CR^1R^2)_t$(4 to 10 membered heterocyclic), $-(CR^1R^2)_tO(CR^1R^2)_q(C_6-C_{10}$ aryl), $-(CR^1R^2)_tO(CR^1R^2)_q$(4 to 10 membered heterocyclic), $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein j is and ~~interger~~ integer from 0 to 2, q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^7$, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5;

each R^{11} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-NR^7SO_2NR^9R^1$, $-NR^7C(O)NR^1R^9$, $-NR^7C(O)OR^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, $-SO_2NR^7R^9$, $-S(O)_j(C_1-C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_qC(O)(CR^1R^2)_t$(4 to 10 membered heterocyclic), $-(CR^1R^2)_tO(CR^1R^2)_q(C_6-C_{10}$ aryl), $-(CR^1R^2)_tO(CR^1R^2)_q$(4 to 10 membered heterocyclic), $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_qS(O)_j(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein j is an integer from 0 to 2, q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^7$, $-C(O)R^7$, $-C(O)OR^7$, $-OC(O)R^7$, $-NR^7C(O)R^9$, $-C(O)NR^7R^9$, $-NR^7R^9$, $-NR^7OR^9$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5;

each R^{13} and R^{14} are independently selected from H, C_1-C_6 alkyl, and $-CH_2OH$;

R^{19} and R^{20} are independently selected from the group consisting of $-(CR^{15}R^{16})_lOR^{17}$ and OR^{18} wherein each R^{15} and R^{16} is independently selected from H, C_1-C_6 alkyl, and $-CH_2OH$, l is an integer from 1 to 3, R^{17} is C_1-C_6 alkyl, R^{18} independently is C_1-C_6 alkyl, provided both R^{19} and R^{20} are not simultaneously $-(CR^{15}R^{16})_lOR^{17}$;

wherein each carbon not bound to a N or O atom, or to $S(O)_j$, wherein j is an integer from 0 to 2, is optionally substituted with R^{12}, wherein R^{12} is R^7, $-OR^7$, $-OC(O)R^7$, $-OC(O)NR^7R^9$, $-OCO_2R^7$, $-S(O)_jR^7$, $-S(O)_jNR^7R^9$, $-NR^7R^9$, $-NR^7C(O)R^9$, $-NR^7SO_2R^9$, $-NR^7C(O)NR^8R^9$, $-NR^7SO_2NR^8R^9$, $-NR^7CO_2R^9$, CN, $-C(O)R^7$, or halo, wherein j is an integer from 0 to 2; and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group, which is not attached to a halogen, SO or SO_2 group or to a N, O or S

atom, is optionally substituted with a group selected from hydroxy, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and $-NR^1R^2$; which comprises reacting a compound of formula **2**



2

wherein X is a halide and R^1, R^3, R^6, R^{11}, m and p are as defined for formula **1** above, with a compound of formula **3**



3

wherein R^4, R^5, R^{13}, R^{14}, R^{19}, R^{20}, and k are as defined for formula **1** above, in the presence of a catalyst, a base, and an optional ligand.

~~2. (Withdrawn) A method for preparing a compound of formula 1~~



1

pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein:

m is an integer from 0 to 3;

p is an integer from 0 to 4;

each R^1, R^2, R^4, and R^5 is independently selected from H and C_1-C_6 alkyl;

R^3 is $-(CR^1R^2)_t$(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, said heterocyclic group is optionally fused to a benzene ring or a C_5-C_8 cycloalkyl group, the $-(CR^1R^2)_t$- moiety of the foregoing R^3 group optionally includes a carbon-carbon double or triple

is prepared by reacting a compound of formula 2A



2A

wherein Y is a halide and X, R^6 and m are as defined for formula 1, with a compound of formula E



E

wherein R^1, R^3, R^{11}, and p are as defined for formula 1.

24. (Original) The method according to claim 1, further comprising converting the compound of formula **1** in one or more steps to produce a compound of formula **5**



5

wherein R^1, R^3, R^4, R^5, R^6, R^{11}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, k, l, m, and p are defined for formula 1 in claim 1.

25. (Original) The method according to claim 24, wherein the compound of formula **5** is selected from the group consisting of :

E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

E-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-2-methoxy-acetamide;

E-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

E-2-Ethoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

E-N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-methanesulfonamide;

and the pharmaceutically acceptable salts, prodrugs and solvates of the foregoing compounds.

26. (Original) The method of claim 24 wherein converting the compound of formula **1** to the compound of formula **5** comprises the steps of :

(a) reacting the compound of formula **1** with an acid to form a compound of formula **4** or a salt thereof



4

and (b) reacting the compound of formula **4** or its salt with $ClC(O)(CR^{15}R^{16})_lOR^{17}$ or a reactive equivalent thereof in the presence of a base to form the compound of formula **5**.

27. (Original) The method according to claim 26, wherein in step (b), the reactive equivalent of $ClC(O)(CR^{15}R^{16})_lOR^{17}$ is an acid imidazole represented by the formula



or an acid anhydride represented by the formula $[R^{17}O(CR^{15}R^{16})_lC(O)]_2O$.

28. (Original) The method according to claim 26, wherein in step (b), the base is at least one compound selected from the group consisting of an aqueous hydroxide of an alkali or alkaline earth metal, a carbonate, phosphate or hydrogen phosphate of an alkaline earth metal, an tertiary amine and DABCO.

29. (Original) The method according to claim 26, wherein step (b) comprises reacting the compound of formula **1** with an acid in one step to produce the compound of formula **5**.

~~30. (Withdrawn) A method for preparing a compound represented by the formula **3a**~~

STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found:***
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library, Remsen Bldg.

C:\Program Files\Stnexp\Queries\10_821906\tru-b.str

structure "L3"



STRUCTURES

chain nodes :
11 18 19 20 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
21 22 23
chain bonds :
7-11 11-13 18-19 19-20 20-21 22-24 23-25
ring/chain bonds :
21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 9-10 11-13 18-19 19-20 20-21
21-22 21-23 22-24 23-25
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS

C:\Program Files\Stnexp\Queries\10_821906\tru-d.str

structure "L11"





chain nodes :
11 18 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
ring/chain nodes :
19 20 21
chain bonds :
7-11 11-13 18-19 19-20 21-22
ring/chain bonds :
20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 9-10 11-13 18-19 19-20 20-21
21-22
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 :

Connectivity :
22:1 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS

22:CLASS 24:CLASS

C:\Program Files\Stnexp\Queries\10_821906\tru-e-reactant.str

structure "L35"





chain nodes :
1 3 10 11 12 16
ring nodes :
4 5 6 7 8 9
chain bonds :
1-3 1-16 3-5 11-12
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9
exact/norm bonds :
1-3 1-16 3-5 11-12
normalized bonds :
4-5 4-9 5-6 6-7 7-8 8-9

G1:[*1],[*2]

Match level :
1:Atom 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS
12:CLASS 16:CLASS
Generic attributes :
1:
Saturation : Unsaturated
Number of Carbon Atoms : 7 or more
Type of Ring System : Polycyclic

Element Count :
Node 1: Limited

N,N2
C,C8
O,O0
S,S0

Registry search for compound 1


```
=> file registry
[redacted]ENTERED AT 15:27:48 ON 20 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 JAN 2006  HIGHEST RN 872163-75-2
DICTIONARY FILE UPDATES:  18 JAN 2006  HIGHEST RN 872163-75-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d stat que L18
L3              STR
```



@18

Page 1-A



Page 2-A
VPA 18-1/2/3/4/9 U
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9

```
NSPEC   IS R       AT  10
NSPEC   IS C       AT  11
NSPEC   IS R       AT  12
NSPEC   IS R       AT  13
NSPEC   IS R       AT  14
NSPEC   IS R       AT  15
NSPEC   IS R       AT  16
NSPEC   IS R       AT  17
NSPEC   IS C       AT  18
NSPEC   IS C       AT  19
NSPEC   IS C       AT  20
NSPEC   IS RC      AT  21
NSPEC   IS RC      AT  22
NSPEC   IS RC      AT  23
NSPEC   IS C       AT  24
NSPEC   IS C       AT  25
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 18 19 20 21 22 23 24 25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L11             STR
```



@18

Page 1-A



Page 2-A
REP G20=(1-6) 19-20 19-18
VPA 18-1/2/3/4/9 U
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS C	AT	18
NSPEC	IS RC	AT	19
NSPEC	IS RC	AT	20
NSPEC	IS RC	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23
CONNECT	IS E1 RC	AT	22

DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11 18 19 20 21 22
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L15 355 SEA FILE=REGISTRY SSS FUL L11
L18 0 SEA FILE=REGISTRY SUB=L15 SSS FUL L3

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

Beilstein search for compound 1


```
> file beilstein
[redacted] ENTERED AT 15:37:15 ON 20 JAN 2006
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON JANUARY 17, 2006

FILE COVERS 1771 TO 2005.
*** FILE CONTAINS  9,428,406 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                 *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE    *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE           *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                         *
* FOR PRICE INFORMATION SEE HELP COST                                 *
**********************************************************************
    NEW
* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE
  SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES,
  ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A
  COMPOUND AT A GLANCE.

=> d stat que L41
L3              STR
```



@18

Page 1-A



Page 2-A
VPA 18-1/2/3/4/9 U
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9

```
NSPEC   IS R      AT  10
NSPEC   IS C      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS RC     AT  21
NSPEC   IS RC     AT  22
NSPEC   IS RC     AT  23
NSPEC   IS C      AT  24
NSPEC   IS C      AT  25
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 18 19 20 21 22 23 24 25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE
L41 STR                0 SEA FILE=BEILSTEIN SSS FUL L3

100.0% PROCESSED    1361 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.11
```

CASREACT search For compound [redacted]

Truong 10/821906 01/20/2006

```
=>  file casreact
FILE 'CASREACT' ENTERED AT 15:29:37 ON 20 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 15 Jan 2006 VOL 144 ISS 3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

*************************************************************
*                                                           *
*     CASREACT now has more than 10 million reactions       *
*                                                           *
*************************************************************

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991)
provided by InfoChem, INPI data prior to 1986, and Biotransformations
database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance
identification.

=> d stat que L19
L11             STR
```



@18

Page 1-A



Page 2-A
REP G20=(1-6) 19-20 19-18
VPA 18-1/2/3/4/9 U
NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS C AT 11
NSPEC IS R AT 12
NSPEC IS R AT 13
NSPEC IS R AT 14
NSPEC IS R AT 15
NSPEC IS R AT 16
NSPEC IS R AT 17
NSPEC IS C AT 18
NSPEC IS RC AT 19
NSPEC IS RC AT 20
NSPEC IS RC AT 21
NSPEC IS C AT 22
NSPEC IS C AT 23
CONNECT IS E1 RC AT 22
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 11 18 19 20 21 22
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L15 355 SEA FILE=REGISTRY SSS FUL L11
L19 0 SEA FILE=CASREACT ABB=ON PLU=ON L15/PRO

Registry/CAPlus search for preparations of compound

Truong 10/821906 01/20/2006

=> file registry
FILE 'REGISTRY' ENTERED AT 15:33:28 ON 20 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JAN 2006 HIGHEST RN 872163-75-2
DICTIONARY FILE UPDATES: 18 JAN 2006 HIGHEST RN 872163-75-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> file caplus
FILE 'CAPLUS' ENTERED AT 15:33:48 ON 20 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 20 Jan 2006 VOL 144 ISS 5
FILE LAST UPDATED: 19 Jan 2006 (20060119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L40
L11 STR



@18

Page 1-A



Page 2-A
REP G20=(1-6) 19-20 19-18
VPA 18-1/2/3/4/9 U
NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2

```
NSPEC   IS R       AT   3
NSPEC   IS R       AT   4
NSPEC   IS R       AT   5
NSPEC   IS R       AT   6
NSPEC   IS R       AT   7
NSPEC   IS R       AT   8
NSPEC   IS R       AT   9
NSPEC   IS R       AT  10
NSPEC   IS C       AT  11
NSPEC   IS R       AT  12
NSPEC   IS R       AT  13
NSPEC   IS R       AT  14
NSPEC   IS R       AT  15
NSPEC   IS R       AT  16
NSPEC   IS R       AT  17
NSPEC   IS C       AT  18
NSPEC   IS RC      AT  19
NSPEC   IS RC      AT  20
NSPEC   IS RC      AT  21
NSPEC   IS C       AT  22
NSPEC   IS C       AT  23
CONNECT IS E1  RC AT  22
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 18 19 20 21 22
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   1
NUMBER OF NODES IS  23

STEREO ATTRIBUTES: NONE
L15          355 SEA FILE=REGISTRY SSS FUL L11
L21           16 SEA FILE=CAPLUS ABB=ON  PLU=ON  L15/PREP
L22          999 SEA FILE=REGISTRY ABB=ON  PLU=ON  (383432-38-0/BI OR 98556-31-1
                 /BI OR 383430-52-2/BI OR 537705-06-9/BI OR 110-91-8/BI OR
                 137632-09-8/BI OR 2450-71-7/BI OR 383432-27-7/BI OR 383433-14-5
                 /BI OR 383434-29-5/BI OR 383434-54-6/BI OR 38870-89-2/BI OR
                 383430-46-4/BI OR 383430-82-8/BI OR 383432-25-5/BI OR 383432-65
                 -3/BI OR 383433-12-3/BI OR 383433-57-6/BI OR 537705-07-0/BI OR
                 537705-08-1/BI OR 537705-10-5/BI OR 202197-26-0/BI OR 230955-75
                 -6/BI OR 287192-97-6/BI OR 287193-30-0/BI OR 350-30-1/BI OR
                 383430-47-5/BI OR 383430-49-7/BI OR 383430-50-0/BI OR 383430-51
                 -1/BI OR 383430-53-3/BI OR 383430-54-4/BI OR 383430-55-5/BI OR
                 383430-69-1/BI OR 383430-73-7/BI OR 383430-77-1/BI OR 383431-07
                 -0/BI OR 383431-08-1/BI OR 383431-09-2/BI OR 383431-59-2/BI OR
                 383431-72-9/BI OR 383431-80-9/BI OR 383432-02-8/BI OR 383432-03
                 -9/BI OR 383432-04-0/BI OR 383432-26-6/BI OR 383432-58-4/BI OR
                 383432-63-1/BI OR 383432-72-2/BI OR 383433-03-2/BI OR 383433-08
                 -7/BI OR 383433-40-7/BI OR 383433-81-6/BI OR 383434-51-3/BI OR
                 383434-53-5/BI OR 383434-56-8/BI OR 383434-57-9/BI OR 537705-05
                 -8/BI OR 7458-03-9/BI OR 79463-77-7/BI OR 92136-39-5/BI OR
                 106-95-6/BI OR 1121-78-4/BI OR 115269-99-3/BI OR 16064-08-7/BI
                 OR 178918-29-1/BI OR 179687-79-7/BI OR 179688-52-9/BI OR
                 179688-53-0/BI OR 202197-31-7/BI OR 204513-31-5/BI OR 31839-20-
                 0/BI OR 31839-21-1/BI OR 3277-47-2/BI OR 3473-63-0/BI OR
                 383430-48-6/BI OR 383430-56-6/BI OR 383430-57-7/BI OR 383430-58
                 -8/BI OR 383430-59-9/BI OR 383430-60-2/BI OR 383430-61-3/BI OR
                 383430-62-4/BI OR 383430-63-5/BI OR 383430-64-6/BI OR 383430-65
                 -7/BI OR 383430-66-8/BI OR 383430-67-9/BI OR 383430-68-0/BI OR
```

383430-70-4/BI OR 383430-71-5/BI OR 383430-72-6/BI OR 383430-74
-8/BI OR 383430-75-9/BI OR 383430-76-0/BI OR 383430-78-2/BI OR
383430-79-3/BI OR 383430-80-6/BI OR 383430-81-7/BI OR 383430-83
-9/BI OR 383430-84-0

L23 500 SEA FILE=REGISTRY ABB=ON PLU=ON (102520-97-8/BI OR 108-95-2/B
I OR 109608-77-7/BI OR 110-91-8/BI OR 120157-98-4/BI OR
123-38-6/BI OR 124-68-5/BI OR 124400-52-8/BI OR 134575-17-0/BI
OR 139-59-3/BI OR 160127-75-3/BI OR 160172-20-3/BI OR 16064-08-
7/BI OR 171178-48-6/BI OR 171349-95-4/BI OR 17823-94-8/BI OR
18994-77-9/BI OR 191284-80-7/BI OR 199538-99-3/BI OR 20734-46-7
/BI OR 2450-71-7/BI OR 255864-58-5/BI OR 26807-73-8/BI OR
275387-76-3/BI OR 275387-83-2/BI OR 287188-70-9/BI OR 287188-71
-0/BI OR 287188-72-1/BI OR 287188-73-2/BI OR 287188-74-3/BI OR
287188-75-4/BI OR 287188-76-5/BI OR 287188-77-6/BI OR 287188-78
-7/BI OR 287188-79-8/BI OR 287188-80-1/BI OR 287188-82-3/BI OR
287188-83-4/BI OR 287188-84-5/BI OR 287188-85-6/BI OR 287188-86
-7/BI OR 287188-87-8/BI OR 287188-88-9/BI OR 287188-89-0/BI OR
287188-90-3/BI OR 287188-91-4/BI OR 287188-92-5/BI OR 287188-93
-6/BI OR 287188-94-7/BI OR 287188-95-8/BI OR 287188-96-9/BI OR
287188-97-0/BI OR 287188-98-1/BI OR 287188-99-2/BI OR 287189-00
-8/BI OR 287189-01-9/BI OR 287189-02-0/BI OR 287189-03-1/BI OR
287189-04-2/BI OR 287189-05-3/BI OR 287189-06-4/BI OR 287189-07
-5/BI OR 287189-08-6/BI OR 287189-09-7/BI OR 287189-10-0/BI OR
287189-11-1/BI OR 287189-12-2/BI OR 287189-13-3/BI OR 287189-14
-4/BI OR 287189-15-5/BI OR 287189-16-6/BI OR 287189-17-7/BI OR
287189-18-8/BI OR 287189-19-9/BI OR 287189-21-3/BI OR 287189-23
-5/BI OR 287189-24-6/BI OR 287189-25-7/BI OR 287189-26-8/BI OR
287189-27-9/BI OR 287189-28-0/BI OR 287189-29-1/BI OR 287189-30
-4/BI OR 287189-31-5/BI OR 287189-32-6/BI OR 287189-33-7/BI OR
287189-34-8/BI OR 287189-35-9/BI OR 287189-36-0/BI OR 287189-37
-1/BI OR 287189-38-2/BI OR 287189-39-3/BI OR 287189-40-6/BI OR
287189-41-7/BI OR 287189-42-8/BI OR 287189-43-9/BI OR 287189-44
-0/BI OR 287189-45-1/BI OR 287189-46-2/BI OR 287189-47-3/BI OR
287189-

L24 1400 SEA FILE=REGISTRY ABB=ON PLU=ON L22 OR L23

L35 STR



Page 1-A

Page 2-A
VAR G1=9/10
NODE ATTRIBUTES:
HCOUNT IS M2 AT 11
NSPEC IS C AT 1
NSPEC IS C AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS C AT 9
NSPEC IS C AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 2 9 10 11
GGCAT IS PCY HIC UNS AT 1
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E8 C E2 N E0 O E0 S AT 1

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L38 49 SEA FILE=REGISTRY SUB=L24 SSS FUL L35
L39 27 SEA FILE=CAPLUS ABB=ON PLU=ON L38 (L) (RCT OR RGT OR RACT)/RL
L40 13 SEA FILE=CAPLUS ABB=ON PLU=ON L39 AND L21

=> d ibib abs hitind hitstr L40 1-13

L40 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:963797 CAPLUS
DOCUMENT NUMBER: 143:254035
TITLE: Crystal forms of (E)-2-methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide for dosage forms
INVENTOR(S): Li, Zheng Jane; Leonard, Jason Albert
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005192298	A1	20050901	US 2005-51145	20050204
WO 2005085229	A1	20050915	WO 2005-IB378	20050214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-548743P P 20040227
AB Crystal forms of (E)-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide (I), useful in the synthesis of salts and complexes of I are described. Crystal forms of I include Form A, Form B, Form C, Form F, Form G, and Form H, and hydrates and/or solvates thereof. A crystal form also improves stability of tabletted or capsuled I as a drug product. For example, a crystal Form A of I was synthesized. First, the reaction of 10.0 g of 6-iodo-4-chloroquinazoline with 7.38 g 3-methyl-4-(6-methylpyridin-3-yloxy)phenylamine in THF at 56° gave 6-iodo[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazoline (15.75 g, 98% yield). The reaction of methoxyacetyl chloride (1.2 equivalent) with propargylamine (1.0 equivalent) in CH2Cl2 at -25° gave 2-methoxyacetic acid propargylamide (7.84 g, 50% yield). 2-Methoxyacetic acid propargylamide (255 mg, 1 equivalent) reacted with 6-iodo[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazoline (1.41 g, 1.5 equivalent) under specific conditions giving the crystal Form A of I (0.55 g, 59% yield).
IC ICM A61K031-517
ICS C07D043-02

INCL 514266210; 544284000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 28, 75
IT **383432-38-0P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(crystal forms of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide for preparation of salts and complexes and oral dosage forms)
IT **537705-05-8P** 537705-07-0P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(crystal forms of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide for preparation of salts and complexes and oral dosage forms)
IT **719270-47-0P 863419-98-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(crystal forms of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide for preparation of salts and complexes and oral dosage forms)
IT **383432-38-0P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(crystal forms of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide for preparation of salts and complexes and oral dosage forms)
RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **537705-05-8P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(crystal forms of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide for preparation of salts and complexes and oral dosage forms)
RN 537705-05-8 CAPLUS

CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-
(9CI) (CA INDEX NAME)



IT **719270-47-0P 863419-98-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(crystal forms of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide for preparation of salts and complexes and oral dosage forms)

RN 719270-47-0 CAPLUS

CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 863419-98-1 CAPLUS
CN Butanedioic acid, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 110-15-6
CMF C4 H6 O4



L40 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:470669 CAPLUS
DOCUMENT NUMBER: 143:155246
TITLE: Evaluation of Kilogram-Scale Sonagashira, Suzuki, and Heck Coupling Routes to Oncology Candidate CP-724,714
AUTHOR(S): Ripin, David H. Brown; Bourassa, Dennis E.; Brandt, Thomas; Castaldi, Michael J.; Frost, Heather N.;

Hawkins, Joel; Johnson, Phillip J.; Massett, Stephen S.; Neumann, Karin; Phillips, James; Raggon, Jeffery W.; Rose, Peter R.; Rutherford, Jennifer L.; Sitter, Barbara; Stewart, A. Morgan, III; Vetelino, Michael G.; Wei, Lulin
CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research Division, Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Organic Process Research & Development (2005), 9(4), 440-450
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis of the anticancer compound 2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}-E-allyl)acetamide (CP-724,714) on multikilogram scale using several different synthetic routes is described. Application of the Sonogashira, Suzuki, and Heck couplings to this synthesis was investigated to identify a safe, environmentally friendly, and robust process for the production of this drug candidate. A convergent and selective synthesis of the candidate was identified which utilizes a Heck coupling of a protected allylamine to install the critical olefin.

CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)
Section cross-reference(s): 28, 63

IT **537705-08-1P 860453-65-2P**
RL: IMF (Industrial manufacture); **PREP (Preparation)**
(evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to methoxy[[[methyl(methylpyridinyloxy)phenylamino]quinazolinyl]allyl]acetamide oncol. candidate)

IT 115269-99-3P, N,N-Bis(tert-butoxycarbonyl)allylamine **383433-14-5P** 486393-59-3P, N-Allylmethoxyacetamide 537705-06-9P, 3-(4-Amino-2-methylphenoxy)-6-methylpyridine 537705-07-0P, N-Propargyl-2-methoxyacetamide **537705-10-5P** 778599-38-5P, tert-Butyl N-allyl-N-(methoxyacetyl)carbamate **778599-39-6P**
RL: IMF (Industrial manufacture); **RCT (Reactant)**; **PREP (Preparation)**; **RACT (Reactant or reagent)**
(precursor; evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to methoxy[[[methyl(methylpyridinyloxy)phenylamino]quinazolinyl]allyl]acetamide oncol. candidate)

IT **537705-08-1P 860453-65-2P**
RL: IMF (Industrial manufacture); **PREP (Preparation)**
(evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to methoxy[[[methyl(methylpyridinyloxy)phenylamino]quinazolinyl]allyl]acetamide oncol. candidate)

RN 537705-08-1 CAPLUS

CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)



RN 860453-65-2 CAPLUS
CN Butanedioic acid, compd. with 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 537705-08-1
CMF C27 H27 N5 O3



CM 2

CRN 110-15-6
CMF C4 H6 O4

$HO_2C-CH_2-CH_2-CO_2H$

IT **383433-14-5P 537705-10-5P 778599-39-6P**
RL: IMF (Industrial manufacture); **RCT (Reactant)**; **PREP (Preparation)**; **RACT (Reactant or reagent)**
(precursor; evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to methoxy[[[methyl(methylpyridinyloxy)phenylamino]quinazolinyl]allyl]acetamide oncol. candidate)

RN 383433-14-5 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 537705-10-5 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 778599-39-6 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propenyl)-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409233 CAPLUS
DOCUMENT NUMBER: 142:463740
TITLE: Preparation of cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
INVENTOR(S): Wallace, Eli; Topolov, George; Zhao, Qian; Lyssikatos, Joseph P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101617	A1	20050512	US 2003-704120	20031110

PRIORITY APPLN. INFO.: US 2003-704120 20031110
OTHER SOURCE(S): MARPAT 142:463740
GI



I



II



III

AB The title compds. I [X = N, CH, C(CN); R1 = substituted (hetero)aryl; R2 = H, halo, CN, etc.; A = II (wherein T = alkyl, alkenyl, cycloalkyl, etc.; L = N, CR4; R4 = H, CF3, alkyl, etc.; Q = (un)substituted CH3, NH2; D = H, CF3, alkyl, etc.; m = 0-1)], useful in the treatment of hyperproliferative diseases, were prepared E.g., a multi-step synthesis of III, starting from 2-amino-5-iodobenzoic acid and formamidine acetate, was given. III showed IC50 of 85 nM in the assay used to determine ErbB kinase activity.

IC ICM A61K031-517
ICS C07D043-02
INCL 514266200; 514266400; 544284000; 544293000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
IT 16064-08-7P 31839-21-1P 98556-31-1P 178918-29-1P 179687-79-7P
179688-52-9P 179688-53-0P 202197-26-0P 202197-31-7P 204513-31-5P
230955-75-6P **383432-25-5P 383433-14-5P** 443882-99-3P
524955-09-7P 529508-58-5P 537705-06-9P **537705-10-5P**
697299-73-3P 697299-74-4P 697299-75-5P 697299-78-8P
697299-81-3P 697299-82-4P 697299-86-8P 697299-87-9P 697299-88-0P
697299-89-1P 697299-90-4P 697299-91-5P 697299-93-7P 697299-94-8P

697299-95-9P **697299-99-3P 697300-01-9P**
697300-04-2P 697300-05-3P 851684-46-3P
851684-76-9P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors for treating hyperproliferative diseases)

IT **383432-25-5P 383433-14-5P 537705-10-5P**
697299-73-3P 697299-74-4P 697299-99-3P
697300-01-9P 697300-04-2P 697300-05-3P
851684-46-3P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors for treating hyperproliferative diseases)

RN 383432-25-5 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propynyl)-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 383433-14-5 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 537705-10-5 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 697299-73-3 CAPLUS
CN Carbamic acid, [3-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 697299-74-4 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propynyl)-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 697299-99-3 CAPLUS
CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-iodo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697300-01-9 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propynyl)-N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 697300-04-2 CAPLUS
CN Carbamic acid, [3-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 697300-05-3 CAPLUS
CN Carbamic acid, [3-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 851684-46-3 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo-, monohydrochloride (9CI) (CA INDEX NAME)



L40 ANSWER 4 OF 13, CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409232 CAPLUS
DOCUMENT NUMBER: 142:463739
TITLE: Preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors
INVENTOR(S): Wallace, Eli; Topalov, George; Lyssikatos, Joseph; Buckmelter, Alexandre; Zhao, Qian
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101616	A1	20050512	US 2003-642440	20030814

US 2005043334 A1 20050224 US 2004-914974 20040810
WO 2005016346 A1 20050224 WO 2004-US26235 20040810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2003-642440 A2 20030814
US 2004-551718P P 20040310
OTHER SOURCE(S): MARPAT 142:463739
GI



I



II



III



IV

AB The title compds. I [A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups; X = N, CH, CF, C(CN); R1 = (un)substituted monocyclic or bicyclic aryl or heteroaryl; R2 = H, (un)substituted alkyl; R3 = H, halo, CN, NO2; A = CH:NN(R8)C(:NR6)NR6R8, UnZ; n = 0-1; U = (un)substituted alkyl, alkenyl, alkynyl; Z = II, III; W, V and Y = CR7R8, CR8R9, O, NR6, S, SO, SO2; R6, R8, R9 = H, CF3, alkyl, etc.; with provisos], useful as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer, were prepared Thus, reacting 4-(3-methyl-4-phenoxyphenylamino)quinazoline-6-carboxaldehyde with hydrazinecarboximidamide in the presence of 1 drop of concentrate HCl in MeOH afforded 68% IV. The compds. I have IC50's from less than 1 nM to 50 μM in EGFR/ErbB2 assays.

IC ICM A61K031-517
ICS C07D043-02; A61K031-47

INCL 514266200; 514266400; 544284000; 544293000; 514313000; 546159000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
IT 79-17-4, Hydrazinecarboximidamide 96-45-7, 2-Imidazolidinethione 109-83-1, 2-Methylaminoethanol 109-96-6, 3-Pyrroline 350-30-1, 2-Chloro-1-fluoro-4-nitrobenzene 556-52-5, Glycidol 753-90-2, 2,2,2-Trifluoroethylamine 872-50-4, 1-Methylpyrrolidin-2-one, reactions 7019-01-4, 4-Benzenesulfonylphenylamine 10200-59-6, 2-Thiazolecarboxaldehyde 13431-10-2 13734-38-8 19815-16-8, 4-Chloro-6-nitroquinazoline 31106-59-9 34064-27-2 72309-96-7 76508-73-1 79463-77-7, Diphenyl N-cyanocarbonimidate 92136-39-5 191284-80-7 202197-26-0 **231278-20-9** 845271-64-9 848482-82-6 851545-81-8
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors for treating hyperproliferative diseases such as cancer)
IT 14542-12-2P, 2-Thiazolemethanol 20112-79-2P 52839-23-3P 56040-95-0P 73286-70-1P 845271-71-8P **851545-71-6P** 851545-72-7P 851545-73-8P 851545-74-9P 851545-75-0P 851545-76-1P 851545-77-2P 851545-78-3P 851545-79-4P 851545-80-7P
RL: RCT (Reactant); SPN (Synthetic preparation); **PREP (Preparation)**; RACT (Reactant or reagent)
(preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors for treating hyperproliferative diseases such as cancer)
IT **231278-20-9**
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(preparation of quinazoline analogs as type I receptor tyrosine kinase inhibitors for treating hyperproliferative diseases such as cancer)
RN 231278-20-9 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo- (9CI) (CA INDEX NAME)



IT **851545-71-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); **PREP (Preparation)**; RACT (Reactant or reagent)
(preparation of quinazoline analogs as type I receptor tyrosine kinase

inhibitors for treating hyperproliferative diseases such as cancer)
RN 851545-71-6 CAPLUS
CN Carbamic acid, [3-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L40 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:872792 CAPLUS
DOCUMENT NUMBER: 141:366242
TITLE: A processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivatives from iodo(amino)quinazoline derivative
INVENTOR(S): Ripin, David Harold Brown; Vetelino, Michael Girard; Wei, Lulin
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089934	A1	20041021	WO 2004-IB1069	20040329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2521348	AA	20041021	CA 2004-2521348		20040329
EP 1615910	A1	20060118	EP 2004-724080		20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
US 2005026940	A1	20050203	US 2004-821906		20040409
PRIORITY APPLN. INFO.:			US 2003-461632P	P	20030409
			US 2003-516860P	P	20031103
			WO 2004-IB1069	W	20040329

OTHER SOURCE(S): MARPAT 141:366242
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a processes for preparing (phenylamino)quinazoline derivs. of formula I [wherein: X is [CH(alkyl)]1-3, (CH2)1-3, or [C(CH2OH)(alkyl)]1-3, etc.; R1, R4, and R5 are independently selected from H or alkyl; R2 is 1-5 substituents; R3 is 0-3 substituents selected from halogen, OH, alkyl, or CF3, etc.; R6 and R7 are independently selected from the group consisting of [C(H/alkyl/CH2OH)(H/alkyl/CH2OH)]1-3-O-alkyl and alkoxy, etc.], useful as antitumor agents (no biol. data). For instance, [(aminoquinazolinyl)allyl]acetamide derivative II [R8 = C(O)CH2OMe] was prepared via aminoalkenylation of iodo(amino)quinazoline derivative III by di-tert-Bu allylamine-N,N-dicarboxylate (example 3, 80% yield) and subsequent amidation of the obtained [(aminoquinazolinyl)allyl]amine derivative II (R8 = H) by methoxyacetyl chloride (example 6, 90-94% yield).

IC ICM C07D401-12

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

IT 115269-99-3P 778599-38-5P **778599-39-6P**
RL: IMF (Industrial manufacture); **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivs. from iodo(amino)quinazoline derivative)

IT **383430-52-2P 383432-38-0P 383432-65-3P**
383433-12-3P 383433-57-6P **537705-08-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); **PREP (Preparation)**
(processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivs. from iodo(amino)quinazoline derivative)

IT 106-95-6, Allyl bromide, reactions 38870-89-2 51779-32-9 486393-59-3
537705-10-5
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivs. from iodo(amino)quinazoline derivative)

IT **778599-39-6P**
RL: IMF (Industrial manufacture); **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivs. from iodo(amino)quinazoline derivative)

RN 778599-39-6 CAPLUS

CN 4-Quinazolinamine, 6-(3-amino-1-propenyl)-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



IT **383430-52-2P 383432-38-0P 383432-65-3P**
383433-12-3P 537705-08-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); **PREP (Preparation)**
(processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivs. from iodo(amino)quinazoline derivative)

RN 383430-52-2 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-65-3 CAPLUS
CN Acetamide, 2-ethoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-12-3 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 537705-08-1 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)



IT **537705-10-5**
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivs. from iodo(amino)quinazoline derivative)
RN 537705-10-5 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:546496 CAPLUS
DOCUMENT NUMBER: 141:106484
TITLE: A preparation of complexes of quinazoline derivative, useful as selective erbB2 inhibitors
INVENTOR(S): Li, Zheng Jane; Leonard, Jason Albert; Trask, Andrew Vincent; Kath, John Charles; Richter, Daniel Tyler; Thompson, Carl Brian; Morris, Joel
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004056802	A1	20040708	WO 2003-IB5783		20031208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2509140	AA	20040708	CA 2003-2509140		20031208
EP 1575936	A1	20050921	EP 2003-775724		20031208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003017259	A	20051108	BR 2003-17259		20031208
US 2005075354	A1	20050407	US 2003-738972		20031217
NL 1025072	A1	20040622	NL 2003-1025072		20031218
PRIORITY APPLN. INFO.:			US 2002-434700P	P	20021219
			WO 2003-IB5783	W	20031208

GI



I



II

AB The invention relates to a preparation of complexes of quinazoline derivative of formula I. The invention also relates to pharmaceutical compns. containing the complexes of formula I. The invention further relates to methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above complexes and to methods of preparing the above complexes. Compound I was prepared via Suzuki coupling of 2-methoxyacetic acid propargylamide and quinazoline derivative II with a yield of 59%.

IC ICM C07D401-12
ICS A61K031-505

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63, 75

IT **719270-48-1P 719270-49-2P 719270-50-5P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)

IT **383432-38-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)

IT **719270-47-0P 719270-51-6P 719270-52-7P**
719270-55-0P 719270-58-3P 719270-61-8P
719270-64-1P 719270-67-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of quinazoline derivative complexes, useful as selective erbB2

inhibitors)

IT **383430-52-2P 383432-27-7P 383434-54-6P**
537705-05-8P 537705-07-0P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)

IT **719270-48-1P 719270-49-2P 719270-50-5P**
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)

RN 719270-48-1 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 719270-49-2 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 719270-50-5 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, phosphate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 7664-38-2
CMF H3 O4 P



IT **383432-38-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)
RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **719270-47-0P 719270-51-6P 719270-52-7P**
719270-55-0P 719270-58-3P 719270-61-8P
719270-64-1P 719270-67-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)
RN 719270-47-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 719270-51-6 CAPLUS
CN 2-Butenedioic acid, 2-methyl-, (2Z)-, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 498-23-7
CMF C5 H6 O4

Double bond geometry as shown.



RN 719270-52-7 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 719270-55-0 CAPLUS
CN 1,2-Ethanedisulfonic acid, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 110-04-3
CMF C2 H6 O6 S2

$HO_3S-CH_2-CH_2-SO_3H$

RN 719270-58-3 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 719270-61-8 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 719270-64-1 CAPLUS

CN Ethanesulfonic acid, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



RN 719270-67-4 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, dinitrate (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 7697-37-2
CMF H N O3



IT **383430-52-2P 383432-27-7P 383434-54-6P**
537705-05-8P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of quinazoline derivative complexes, useful as selective erbB2 inhibitors)

RN 383430-52-2 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-27-7 CAPLUS
CN 4-Quinazolinamine, 6-[(1E)-3-amino-1-propenyl]-N-[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-54-6 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 537705-05-8 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:453176 CAPLUS
DOCUMENT NUMBER: 141:7132
TITLE: Preparation of cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives as ErbB2 and EGFR inhibitors
INVENTOR(S): Wallace, Eli; Topalov, George; Zhao, Qian
PATENT ASSIGNEE(S): Array Biopharma, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046101	A2	20040603	WO 2003-US35670	20031110
WO 2004046101	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506503	AA	20040603	CA 2003-2506503	20031110
EP 1567506	A2	20050831	EP 2003-768789	20031110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-427544P P 20021120
WO 2003-US35670 W 20031110

OTHER SOURCE(S): MARPAT 141:7132
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein one of the positions 6 or 7 of the quinazoline ring must be substituted by A, and the remaining positions optionally substituted by R2; X = N, CH, C-CN; R1 = independently hetero/aryl substituted by at least one R6 and optionally substituted by up to three R5 groups; R5 = CN, Cl, F, Br, lower alkyl, CF3, CHF2, NO2, OH and derivs.; R6 = H, CN, Cl, F, Br, CF3, CHF2, OCF3, NO2, (un)substituted cycloalkyl/aryl/heteroaryl/cyclo/heterocyclyl/alkyl, hetero/aryl, alkenyl, alkynyl, heterocyclyl; A = -(T)m-L(D)-C(:N-CN)Q; T = (un)substituted cycloalkyl/aryl/heteroaryl/cyclo/heterocyclyl/alkyl, hetero/aryl, alkenyl, alkynyl, heterocyclyl; m = 0-1; L = N, CH, CF3, (un)substituted alk(en/yn)yl, hetero/aryl, etc.; Q = CH3 and derivs. with provisos; D = H, CF3, CHF2, SO2NH2 and derivs., CO2H and derivs., CONH2 and derivs., (un)substituted alk(en/yn)yl, hetero/aryl, etc.; their enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and prodrugs] were prepared as ErbB2 and EGFR inhibitors for treating proliferative diseases. Alkylation of 3-chloro-4-(3-fluorobenzyloxy)phenylamine (preparation given) with 4-chloro-6-iodoquinazoline (preparation given), Pd-cross coupling of the iodide with (prop-2-ynyl)carbamic acid tert-Bu ester, and BOC-deprotection gave the amine II. Condensation of amine II with di-Ph cyanocarbonimidate, and reaction with NHMe2 gave the quinazoline cyanoguanidine III. Selected I modulated ErbB kinase activity with IC50 values in the range of 8-33 nM. I are useful for treating cancer and inflammation.

IC ICM C07D

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 16064-08-7P 31839-21-1P, 2-Amino-5-hydroxy-4-methoxybenzoic acid 98556-31-1P, 4-Chloro-6-iodoquinazoline 178918-29-1P, (Furan-2-ylmethyl)carbamic acid tert-butyl ester 179687-79-7P, 2-[(2-Chloro-4-nitrophenoxy)methyl]pyridine 179688-52-9P, 7-Methoxyquinazoline-4,6-diol 179688-53-0P, Acetic acid 4-hydroxy-7-methoxyquinazolin-6-yl ester 202197-26-0P, [3-Chloro-4-(3-fluorobenzyloxy)phenyl]amine 202197-31-7P, [1-(3-Fluorobenzyl)-1H-indazol-5-yl]amine 230955-75-6P, Acetic acid 4-chloro-7-methoxyquinazolin-6-yl ester **383432-25-5P**, [6-(3-Aminoprop-1-ynyl)quinazolin-4-yl][3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amine **383433-14-5P**, [3-[4-[[3-Methyl-4-(6-methylpyridin-3-yloxy)phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester 443882-99-3P, 2-Chloro-1-(3-fluorobenzyloxy)-4-nitrobenzene 524955-09-7P, [3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amine 529508-58-5P, 1-(3-Fluorobenzyl)-5-nitro-1H-indazole 537705-06-9P, [3-Methyl-4-(6-methylpyridin-3-yloxy)phenyl]amine **697299-72-2P**, [3-Chloro-4-(3-fluorobenzyloxy)phenyl](6-iodoquinazolin-4-yl)amine hydrochloride **697299-73-3P**, [3-[4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester **697299-74-4P**, [6-(3-Aminoprop-1-ynyl)quinazolin-4-yl][3-chloro-4-(3-fluorobenzyloxy)phenyl]amine 697299-75-5P, 1-[3-[4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]quinazolin-6-yl]prop-2-ynyl]-2-phenyl-3-cyanoisourea 697299-78-8P, 2-Methyl-5-(2-methyl-4-nitrophenoxy)pyridine **697299-79-9P**, (6-Iodoquinazolin-4-yl)[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amine hydrochloride

697299-81-3P, [[5-[4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]quinazolin-6-yl]furan-2-yl]methyl]carbamic acid tert-butyl ester 697299-82-4P, [6-(5-Aminomethylfuran-2-yl)quinazolin-4-yl][3-chloro-4-(3-fluorobenzyloxy)phenyl]amine 697299-83-5P, 1-[[5-[4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]quinazolin-6-yl]furan-2-yl]methyl]-2-phenyl-3-cyanoisourea 697299-86-8P, [(4-Bromothiazol-2-yl)methyl]amine 697299-87-9P, (4-Bromothiazol-2-ylmethyl)carbamic acid tert-butyl ester 697299-88-0P, [4-(Trimethylstannyl)thiazol-2-ylmethyl]carbamic acid tert-butyl ester 697299-89-1P, [[4-[4-[[3-Methyl-4-(6-methylpyridin-3-yloxy)phenyl]amino]quinazolin-6-yl]thiazol-2-yl]methyl]carbamic acid tert-butyl ester 697299-90-4P, [6-(2-Aminomethylthiazol-4-yl)quinazolin-4-yl][3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amine 697299-91-5P, 1-[[4-[4-[[3-Methyl-4-(6-methylpyridin-3-yloxy)phenyl]amino]quinazolin-6-yl]thiazol-2-yl]methyl]-2-phenyl-3-cyanoisourea 697299-93-7P, 4-[[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-7-methoxyquinazolin-6-ol 697299-94-8P, [3-[[4-[[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-7-methoxyquinazolin-6-yl]oxy]propyl]carbamic acid tert-butyl ester 697299-95-9P, [6-(3-Aminopropoxy)-7-methoxyquinazolin-4-yl][3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amine **697299-99-3P**, [1-(3-Fluorobenzyl)-1H-indazol-5-yl](6-iodoquinazolin-4-yl)amine hydrochloride **697300-00-8P**, [3-[4-[1-(3-Fluorobenzyl)-1H-indazol-5-ylamino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester **697300-01-9P**, [6-(3-Aminoprop-1-ynyl)quinazolin-4-yl][1-(3-fluorobenzyl)-1H-indazol-5-yl]amine 697300-02-0P, 1-[3-[4-[1-(3-Fluorobenzyl)-1H-indazol-5-ylamino]quinazolin-6-yl]prop-2-ynyl]-2-phenyl-3-cyanoisourea **697300-04-2P**, [3-[4-[[1-(3-Fluorobenzyl)-1H-indazol-5-yl]amino]quinazolin-6-yl]allyl]carbamic acid tert-butyl ester
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(intermediate; preparation of quinazolinylcyanoguanidines and quinazolaminocyanoamidines as ErbB2 and EGFR inhibitors)

IT 110-91-8, Morpholine, reactions 350-30-1, 2-Chloro-1-fluoro-4-nitrobenzene 455-88-9, 4-Fluoro-3-methylnitrobenzene 456-41-7, 3-Fluorobenzyl bromide 456-47-3, (3-Fluorophenyl)methanol 586-98-1, Pyridin-2-ylmethanol 617-89-0, (Furan-2-ylmethyl)amine 661-69-8, Hexamethylditin 1121-78-4, 6-Methylpyridin-3-ol 3277-47-2, 2-Phenyl-N-cyanoisourea 4175-77-3, 2,4-Dibromothiazole 5326-47-6, 2-Amino-5-iodobenzoic acid 5401-94-5, 5-Nitroindazole 31839-20-0, 5-Hydroxy-4-methoxy-2-nitrobenzoic acid 79463-77-7, Diphenyl cyanocarbonimidate 83948-53-2, (3-Bromopropyl)carbamic acid tert-butyl ester 92136-39-5, (Prop-2-ynyl)carbamic acid tert-butyl ester 204513-31-5, (4-Bromothiazol-2-yl)methanol 697299-85-7, 2-Azidomethyl-4-bromothiazole 697300-05-3 **697300-06-4**, [6-(3-Aminopropen-1-yl)quinazolin-4-yl][1-(3-fluorobenzyl)-1H-indazol-5-yl]amine 697300-07-5, 1-[3-[4-[[1-(3-Fluorobenzyl)-1H-indazol-5-yl]amino]quinazolin-6-yl]allyl]-2-phenyl-3-cyanoisourea
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(preparation of quinazolinylcyanoguanidines and quinazolaminocyanoamidines as ErbB2 and EGFR inhibitors)

IT **383432-25-5P**, [6-(3-Aminoprop-1-ynyl)quinazolin-4-yl][3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amine **383433-14-5P**, [3-[4-[[3-Methyl-4-(6-methylpyridin-3-yloxy)phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester **697299-72-2P**, [3-Chloro-4-(3-fluorobenzyloxy)phenyl](6-iodoquinazolin-4-yl)amine hydrochloride **697299-73-3P**, [3-[4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester **697299-74-4P**, [6-(3-Aminoprop-1-ynyl)quinazolin-4-yl][3-chloro-4-(3-fluorobenzyloxy)phenyl]amine **697299-79-9P**, (6-Iodoquinazolin-4-yl)[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amine

hydrochloride **697299-99-3P**, [1-(3-Fluorobenzyl)-1H-indazol-5-yl](6-iodoquinazolin-4-yl)amine hydrochloride **697300-00-8P**, [3-[4-[1-(3-Fluorobenzyl)-1H-indazol-5-ylamino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester **697300-01-9P**, [6-(3-Aminoprop-1-ynyl)quinazolin-4-yl][1-(3-fluorobenzyl)-1H-indazol-5-yl]amine **697300-04-2P**, [3-[4-[[1-(3-Fluorobenzyl)-1H-indazol-5-yl]amino]quinazolin-6-yl]allyl]carbamic acid tert-butyl ester
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(intermediate; preparation of quinazolinylcyanoguanidines and quinazolaminocyanoamidines as ErbB2 and EGFR inhibitors)

RN 383432-25-5 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propynyl)-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 383433-14-5 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 697299-72-2 CAPLUS
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo-, hydrochloride (9CI) (CA INDEX NAME)



RN 697299-73-3 CAPLUS
CN Carbamic acid, [3-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 697299-74-4 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propynyl)-N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 697299-79-9 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 697299-99-3 CAPLUS
CN 4-Quinazolinamine, N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]-6-iodo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 697300-00-8 CAPLUS
CN Carbamic acid, [3-[4-[[(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 697300-01-9 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propynyl)-N-[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 697300-04-2 CAPLUS
CN Carbamic acid, [3-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **697300-06-4**, [6-(3-Aminopropen-1-yl)quinazolin-4-yl][1-(3-fluorobenzyl)-1H-indazol-5-yl]amine
RL: **RCT (Reactant); RACT (Reactant or reagent)**
(preparation of quinazolinylcyanoguanidines and quinazolaminocyanoamidines as ErbB2 and EGFR inhibitors)
RN 697300-06-4 CAPLUS
CN 4-Quinazolinamine, 6-(3-amino-1-propenyl)-N-[1-[(3-fluorophenyl)methyl]-1H-

indazol-5-yl]- (9CI) (CA INDEX NAME)



L40 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:472506 CAPLUS
DOCUMENT NUMBER: 139:41834
TITLE: Preparation of (E)-2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}allyl)acetamide salts
INVENTOR(S): Richter, Daniel Tyler; Kath, John Charles
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050108	A1	20030619	WO 2002-IB4708	20021111
WO 2003050108	C1	20031218		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469889	AA	20030619	CA 2002-2469889	20021111
EP 1456199	A1	20040915	EP 2002-804543	20021111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014876	A	20041228	BR 2002-14876	20021111
JP 2005511744	T2	20050428	JP 2003-551132	20021111
US 2003158217	A1	20030821	US 2002-315862	20021210
US 6844349	B2	20050118		
ZA 2004002995	A	20050420	ZA 2004-2995	20040420
NO 2004002925	A	20040907	NO 2004-2925	20040709
PRIORITY APPLN. INFO.:			US 2001-340885P P	20011212
			WO 2002-IB4708 W	20021111

AB The invention relates to succinate and malonate salts of

(E)-2-methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)phenylamino]quinazolin-6-yl}allyl)acetamide (I). More particularly, the present invention relates to pharmaceutical compns. containing sesqui-succinate and dimalonate salts of I. The invention further relates to methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above salts. A salt was prepared by the reaction of the quinazolinylallylacetamide derivative with malonic acid.

IC ICM C07D401-12
ICS A61K031-505

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 28

IT **383430-52-2P 383432-27-7P 383432-38-0P 383434-54-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide salts)

IT **543681-31-8P 543681-32-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide salts)

IT **383430-52-2P 383432-27-7P 383432-38-0P 383434-54-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide salts)

RN 383430-52-2 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-27-7 CAPLUS
CN 4-Quinazolinamine, 6-[(1E)-3-amino-1-propenyl]-N-[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-54-6 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **543681-31-8P 543681-32-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of methoxy(methyl(methylpyridinyloxy)phenylamino)quinazolinylallylacetamide salts)
RN 543681-31-8 CAPLUS
CN Butanedioic acid, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 110-15-6
CMF C4 H6 O4

$HO_2C-CH_2-CH_2-CO_2H$

RN 543681-32-9 CAPLUS
CN Propanedioic acid, compd. with 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]acetamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 383432-38-0
CMF C27 H27 N5 O3

Double bond geometry as shown.



CM 2

CRN 141-82-2
CMF C3 H4 O4

$HO_2C-CH_2-CO_2H$

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:472389 CAPLUS
DOCUMENT NUMBER: 139:36543
TITLE: Preparation of quinazoline derivatives for the treatment of abnormal cell growth
INVENTOR(S): Kath, John Charles; Moyer, James Dale; Connell, Richard Damian
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049740	A1	20030619	WO 2002-IB4636	20021104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469670	AA	20030619	CA 2002-2469670	20021104
EP 1465632	A1	20041013	EP 2002-777736	20021104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002014499	A	20050510	BR 2002-14499			20021104
JP 2005527486	T2	20050915	JP 2003-550789			20021104
US 2003171386	A1	20030911	US 2002-315863			20021210
NO 2004002882	A	20040707	NO 2004-2882			20040707
PRIORITY APPLN. INFO.:			US 2001-341091P		P	20011212
			WO 2002-IB4636		W	20021104

OTHER SOURCE(S): MARPAT 139:36543

GI



I

AB This invention relates to quinazoline derivs. that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. For instance, 4-ethynylpiperidine-1-carboxylic acid tert-Bu ester is coupled to 4-chloro-6-iodoquinazoline (THF, i-Pr2NH, (Ph3P)2PdCl2, CuI) and the product reacted with 3-Methyl-4-[pyridin-3-yloxy]phenylamine (dichloroethane, t-BuOH, 90°) and finally treated with HCl gas to give I. The invention further relates to small mols. that are selective for erbB2 receptor over the erbB1 receptor, wherein said erbB2 inhibitor has a range of selectivities for erbB2 over erbB1 between 50-1500.

IC ICM A61K031-517
ICS A61P035-00; C07D401-12

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 383430-46-4P, [3-Methyl-4-[pyridin-3-yloxy]phenyl][6-[piperidin-4-ylethynyl]quinazolin-4-yl]amine **383430-48-6P**, 2-Dimethylamino-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide hydrochloride **383430-49-7P**, N-[3-[4-[[3-Chloro-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]-N'-methylurea 383430-51-1P, [3-Methyl-4-[pyridin-3-yloxy]phenyl][6-[3-[morpholin-4-yl]propenyl]quinazolin-4-yl]amine **383430-52-2P** **383430-53-3P** **383430-54-4P**, (E)-2-Hydroxy-N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]isobutyramide **383430-77-1P**, [3-[4-[[3-Methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid methyl ester **383430-82-8P**, 2-Dimethylamino-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide **383432-03-9P**, N-[3-[4-[[3-Chloro-4-[pyridin-3-

yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]-N'-ethylurea **383432-04-0P**, N-Ethyl-N'-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]urea **383432-38-0P** **383432-63-1P**, (E)-Cyclopropanecarboxylic acid N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide **383432-72-2P**, (E)-Cyclopropanecarboxylic acid N-[3-[4-[[3-chloro-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide **383434-46-6P**, (E)-[3-[4-[[3-Methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]carbamic acid methyl ester **383434-48-8P**, (E)-Cyclopropanecarboxylic acid N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide **544437-84-5P**, 2-Chloro-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide hydrochloride 544437-85-6P, N-[3-[4-[5-Methyl-6-phenoxypyridin-3-ylamino]quinazolin-6-yl]prop-2-ynyl]-2-oxopropionamide **544437-86-7P**, 2-Methoxy-N-[3-[4-[[4-[3-methoxyphenoxy]-3-methylphenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide **544437-87-8P**, (E)-5-Methylisoxazole-3-carboxylic acid N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide **544437-88-9P**, 3-Methoxypyrrolidine-1-carboxylic acid N-[1,1-dimethyl-3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]amide **544437-89-0P**, 3-Methylisoxazole-5-carboxylic acid N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(quinazoline derivs. for treatment of abnormal cell growth)

IT 110-91-8, Morpholine, reactions 7458-03-9, 2-Chloro-N-prop-2-ynylacetamide 40635-66-3, 2-Acetoxyisobutyryl chloride 63126-47-6, (+)-(S)-2-[Methoxymethyl]pyrrolidine 98556-31-1, 4-Chloro-6-iodoquinazoline 287192-97-6, 4-Ethynylpiperidine-1-carboxylic acid tert-butyl ester 383430-47-5, 2-Chloro-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide 383430-73-7, 3-[4-[[3-Methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-yn-1-ol **383432-26-6** 383434-29-5, [3-[4-[[3-Chloro-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid tert-butyl ester 383434-56-8, 3-Methyl-4-[pyridin-3-yloxy]phenylamine 383434-57-9, [3-[4-[[3-Chloro-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid phenyl ester
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(quinazoline derivs. for treatment of abnormal cell growth)

IT 287193-30-0P, 2-Chloro-N-[3-[4-chloroquinazolin-6-yl]prop-2-ynyl]acetamide **383432-27-7P** 383434-51-3P, 4-[4-Chloroquinazolin-6-ylethynyl]piperidine-1-carboxylic acid tert-butyl ester 383434-53-5P, [6-[3-Chloropropenyl]quinazolin-4-yl][3-methyl-4-[pyridin-3-yloxy]phenyl]amine **383434-54-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(quinazoline derivs. for treatment of abnormal cell growth)

IT **383430-48-6P**, 2-Dimethylamino-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide hydrochloride **383430-49-7P**, N-[3-[4-[[3-Chloro-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]-N'-methylurea **383430-52-2P** **383430-53-3P** **383430-54-4P**, (E)-2-Hydroxy-N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]isobutyramide **383430-77-1P**, [3-[4-[[3-Methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]carbamic acid methyl ester

383430-82-8P, 2-Dimethylamino-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide
383432-03-9P, N-[3-[4-[[3-Chloro-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]-N'-ethylurea
383432-04-0P, N-Ethyl-N'-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]urea **383432-38-0P**
383432-63-1P, (E)-Cyclopropanecarboxylic acid N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide
383432-72-2P, (E)-Cyclopropanecarboxylic acid N-[3-[4-[[3-chloro-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide
383434-46-6P, (E)-[3-[4-[[3-Methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]carbamic acid methyl ester
383434-48-8P, (E)-Cyclopropanecarboxylic acid N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide
544437-84-5P, 2-Chloro-N-[3-[4-[[3-methyl-4-[pyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide hydrochloride
544437-86-7P, 2-Methoxy-N-[3-[4-[[4-[3-methoxyphenoxy]-3-methylphenyl]amino]quinazolin-6-yl]prop-2-ynyl]acetamide
544437-87-8P, (E)-5-Methylisoxazole-3-carboxylic acid N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]allyl]amide **544437-88-9P**, 3-Methoxypyrrolidine-1-carboxylic acid N-[1,1-dimethyl-3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]amide **544437-89-0P**, 3-Methylisoxazole-5-carboxylic acid N-[3-[4-[[3-methyl-4-[6-methylpyridin-3-yloxy]phenyl]amino]quinazolin-6-yl]prop-2-ynyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(quinazoline derivs. for treatment of abnormal cell growth)

RN 383430-48-6 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383430-49-7 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 383430-52-2 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383430-53-3 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(methoxymethyl)-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383430-54-4 CAPLUS
CN Propanamide, 2-hydroxy-2-methyl-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383430-77-1 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383430-82-8 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-03-9 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 383432-04-0 CAPLUS
CN Urea, N-ethyl-N'-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-63-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-72-2 CAPLUS
CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-46-6 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-48-8 CAPLUS

CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 544437-84-5 CAPLUS
CN Acetamide, 2-chloro-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 544437-86-7 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[4-(3-methoxyphenoxy)-3-methylphenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 544437-87-8 CAPLUS
CN 3-Isoxazolecarboxamide, 5-methyl-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 544437-88-9 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 544437-89-0 CAPLUS
CN 5-Isoxazolecarboxamide, 3-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



IT **383432-26-6**
RL: **RCT (Reactant); RACT (Reactant or reagent)**
(quinazoline derivs. for treatment of abnormal cell growth)
RN 383432-26-6 CAPLUS
CN 4-Quinazolinamine, 6-[(1E)-3-amino-1-propenyl]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **383432-27-7P 383434-54-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(quinazoline derivs. for treatment of abnormal cell growth)
RN 383432-27-7 CAPLUS
CN 4-Quinazolinamine, 6-[(1E)-3-amino-1-propenyl]-N-[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-54-6 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:434552 CAPLUS
DOCUMENT NUMBER: 139:22223
TITLE: Processes for the preparation of substituted arylaminoquinazolines for the treatment of abnormal cell growth
INVENTOR(S): Ripin, David Harold Brown
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045939	A1	20030605	WO 2002-IB4097	20021003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462149	AA	20030605	CA 2002-2462149	20021003
EP 1448551	A1	20040825	EP 2002-772689	20021003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014606	A	20040914	BR 2002-14606	20021003
JP 2005515986	T2	20050602	JP 2003-547389	20021003
US 2003144506	A1	20030731	US 2002-307603	20021202
ZA 2004002054	A	20050523	ZA 2004-2054	20040315
PRIORITY APPLN. INFO.:			US 2001-334647P P	20011130
			WO 2002-IB4097 W	20021003

OTHER SOURCE(S): MARPAT 139:22223
GI



I



II

AB Arylaminoquinazolines I [R1 = H, alkyl; R2 = halo, CN, NO2, F3CO, F3C, N3, (un)substituted OH, NH2, alkyl, alkenyl, alkynyl, acyl; R3 = heterocyclyl, heterocyclylalkyl; R4 = (un)substituted alkynyl, alkenyl; R5 = halo, (un)substituted OH NH2, alkyl, CONH2, SO2NH2; m = 0-3; n = 0-4] were prepared for use in treating abnormal cell growth in mammals (no data). Thus, 4-chloro-6-iodoquinazoline was treated with 3-(4-amino-2-methylphenoxy)-6-methylpyridine to give the aminoquinazoline II [R6 = I] which was treated with MeOCH2CONHCH2C.tplbond.CH under Suzuki coupling conditions to give II [R6 = MeOCH2CONHCH2CH:CH].

IC ICM C07D401-12
ICS C07F005-02; C07C235-04

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT **537705-05-8P** 537705-07-0P, N-Propargyl-2-methoxyacetamide
537705-09-2P **537705-10-5P** **537705-11-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(processes for the preparation of substituted arylaminoquinazolines for the treatment of abnormal cell growth)

IT 383430-46-4P **383430-52-2P** 383430-55-5P **383430-69-1P**
383430-82-8P 383431-07-0P 383431-08-1P **383431-09-2P**
383431-59-2P **383431-72-9P** **383431-80-9P**
383432-02-8P **383432-38-0P** **383432-58-4P**
383432-65-3P **383433-03-2P** **383433-08-7P**
383433-12-3P **383433-40-7P** 383433-57-6P
383433-81-6P **537705-08-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(processes for the preparation of substituted arylaminoquinazolines for the treatment of abnormal cell growth)

IT **537705-05-8P** **537705-10-5P** **537705-11-6P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(processes for the preparation of substituted arylaminoquinazolines for the

treatment of abnormal cell growth)
RN 537705-05-8 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 537705-10-5 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 537705-11-6 CAPLUS
CN 4-Quinazolinamine, 6-chloro-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



IT **383430-52-2P 383430-69-1P 383430-82-8P**
383431-09-2P 383431-59-2P 383431-72-9P
383431-80-9P 383432-02-8P 383432-38-0P
383432-58-4P 383432-65-3P 383433-03-2P
383433-08-7P 383433-12-3P 383433-40-7P
383433-81-6P 537705-08-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(processes for the preparation of substituted arylaminoquinazolines for the treatment of abnormal cell growth)

RN 383430-52-2 CAPLUS

CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383430-69-1 CAPLUS

CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-82-8 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-09-2 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-59-2 CAPLUS
CN Acetamide, 2-fluoro-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-72-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-80-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-02-8 CAPLUS
CN Urea, N-ethyl-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-58-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-65-3 CAPLUS
CN Acetamide, 2-ethoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-03-2 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(hydroxymethyl)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-08-7 CAPLUS
CN Acetamide, 2-methoxy-N-[1-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]ethynyl]cyclopropyl]- (9CI) (CA INDEX NAME)



RN 383433-12-3 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-40-7 CAPLUS
CN Urea, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 383433-81-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 537705-08-1 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:658094 CAPLUS
DOCUMENT NUMBER: 137:185509
TITLE: Preparation of 4-phenylaminoquinazoline derivatives as inhibitors of tyrosine-specific protein kinase
INVENTOR(S): Kitano, Yasunori; Kawahara, Eiji; Suzuki, Tsuyoshi; Abe, Daisuke; Nakajou, Masahiro; Ueda, Naoko
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan

SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066445	A1	20020829	WO 2002-JP1575	20020221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2442742	AA	20020829	CA 2002-2442742	20020221
EP 1369418	A1	20031210	EP 2002-700688	20020221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1492860	A	20040428	CN 2002-805260	20020221
US 2004116422	A1	20040617	US 2003-468788	20030821
PRIORITY APPLN. INFO.:			JP 2001-45827 A	20010221
			JP 2001-353525 A	20011119
			WO 2002-JP1575 W	20020221

OTHER SOURCE(S): MARPAT 137:185509
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. represented by the following general formula (I) or pharmaceutically acceptable salts thereof, hydrates or solvates of the same or mixts. of optically active isomers, racemic compds. or diastereomers of the same [n = an integer of 0-3; R1 = H, halo, HO, cyano, NO2, CF3, C1-5 alkyl, C1-5 alkoxy, S(O)f-C1-5 alkyl (wherein f = an integer of 0-2), (un)substituted NH2; one of R2 and R2 is R27SO2NH, (R28SO2)2N, C1-5 alkoxy, MeCOCH2CONH, MeSCH2CH2OCONH, or NCCH2CONH, etc. (wherein R27, R28 = optionally morpholino-substituted C1-5 alkyl) and the other one represents Y(CR12R13)mCR8R9C.tplbond.C, Y(CR12R13)mCR8R9CH:CH, Q, Q1 (wherein R8, R9 = H, optionally HO- or C1-5 alkoxy substituted C1-5 alkyl, or CR8 R9 together represent CO or C3-8 cycloalkylene optionally interrupted by O, S, NH, or alkyl-N; Y = H,HO, C1-5 alkoxy, C1-5 alkanoyloxy, etc.; R11, R12 = H, C1-5 alkyl; m = an integer of 0-3; p, q = 2,3; Z = O, S, SO, SO2, CO, optionally substituted NH; p1, p2 = an integer of 1-3; n1 = 0,1; W = H,HO, C1-5 alkoxy, C1-5 alkanoyloxy, CO2H, cyano, di-C1-5 alkyamino, morpholino, etc.)] are prepared These compds. have an excellent protein kinase inhibitory activity specific to tyrosine and, therefore, are usable as drugs, in particular, remedies/preventives for various cancers, diseases caused by arteriosclerosis or psoriasis. Thus, 1-(1,1-dimethyl-2-propynyl)-4-methylpiperazine was treated with 4,4,5,5-tetramethyl-1,3,2-dioxaborane in the presence of PhCl(PPh3)3 in THF/CH2Cl2 at room temperature and coupled with 4-(3-chloro-4-fluorophenylamino)-

6-methoxy-7-quinazolinyl triflate (preparation given) in the presence of PdCl2(dppf).CH2Cl2 [dppf = 1,1'-bis(diphenylphosphino)ferrocene] in a mixture of DMF and 2 m aqueous Na2CO3 80° for 1 h to give the title compound (II). II.HCl showed IC50 of 0.82 nM against EGF receptor tyrosine kinase.

IC ICM C07D239-94
ICS C07D401-06; C07D401-12; C07D405-06; A61K031-517; A61K031-5377; A61K031-551; A61P043-00; A61P035-00; A61P009-10; A61P017-06

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7

IT 451492-95-8P 451492-96-9P 451492-97-0P 451492-99-2P 451493-00-8P
451493-01-9P 451493-02-0P 451493-03-1P 451493-04-2P 451493-05-3P
451493-06-4P 451493-07-5P 451493-08-6P 451493-09-7P 451493-10-0P
451493-11-1P 451493-12-2P 451493-13-3P 451493-14-4P 451493-15-5P
451493-16-6P 451493-17-7P 451493-18-8P 451493-19-9P 451493-20-2P
451493-22-4P 451493-25-7P 451493-28-0P 451493-29-1P 451493-30-4P
451493-31-5P 451493-32-6P 451493-33-7P 451493-34-8P 451493-35-9P
451493-36-0P 451493-37-1P 451493-38-2P 451493-39-3P 451493-40-6P
451493-41-7P 451493-42-8P 451493-44-0P 451493-45-1P 451493-46-2P
451493-47-3P 451493-48-4P 451493-49-5P 451493-50-8P 451493-51-9P
451493-52-0P 451493-53-1P 451493-54-2P 451493-55-3P 451493-56-4P
451493-57-5P 451493-58-6P 451493-59-7P 451493-60-0P 451493-61-1P
451493-63-3P 451493-64-4P 451493-65-5P 451493-66-6P 451493-67-7P
451493-68-8P 451493-69-9P 451493-70-2P 451493-71-3P 451493-72-4P
451493-73-5P 451493-74-6P 451493-75-7P 451493-76-8P 451493-77-9P
451493-78-0P 451493-79-1P 451493-80-4P 451493-81-5P 451493-82-6P
451493-83-7P 451493-84-8P 451493-85-9P 451493-86-0P 451493-87-1P
451493-88-2P 451493-89-3P 451493-90-6P 451493-91-7P 451493-92-8P
451493-93-9P 451493-94-0P 451493-95-1P 451493-96-2P 451493-97-3P
451493-98-4P 451493-99-5P 451494-00-1P 451494-01-2P 451494-02-3P
451494-03-4P 451494-04-5P 451494-05-6P 451494-06-7P 451494-07-8P
451494-08-9P 451494-09-0P 451494-10-3P 451494-11-4P 451494-12-5P
451494-13-6P 451494-14-7P 451494-15-8P 451494-16-9P 451494-18-1P
451494-20-5P **451494-21-6P** 451494-25-0P 451494-27-2P
451494-28-3P 451494-29-4P 451494-98-7P 451495-01-5P 451495-11-7P
451495-12-8P 451498-59-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of phenylaminoquinazoline derivs. as inhibitors of tyrosine-specific protein kinase for preparation and/or treatment of cancers, diseases caused by arteriosclerosis, or psoriasis)

IT 63-68-3, L-Methionine, reactions 68-12-2, DMF, reactions 78-77-3, Isobutyl bromide 79-10-7, Acrylic acid, reactions 99-03-6 99-98-9, N,N-Dimethyl-1,4-diaminobenzene 106-94-5, Propyl bromide 107-13-1, Acrylonitrile, reactions 108-24-7, Acetic anhydride 108-44-1, m-Tolylamine, reactions 109-01-3, 1-Methylpiperazine 110-85-0, Piperazine, reactions 110-91-8, Morpholine, reactions 124-63-0, Methanesulfonyl chloride 358-23-6, Trifluoromethanesulfonic anhydride 367-21-5, 3-Chloro-4-fluoroaniline 372-09-8, Cyanoacetic acid 506-59-2, Dimethylamine hydrochloride 536-90-3, 3-Methoxyaniline 544-92-3, Copper(I) cyanide 590-17-0, Bromoacetonitrile 627-41-8, 3-Methoxypropyne 627-42-9, 2-Chloroethyl methyl ether 674-82-8, Ketene dimer 925-90-6, Ethylmagnesium bromide 1126-09-6 1604-29-1 1622-32-8, 2-Chloroethanesulfonyl chloride 2237-30-1, 3-Aminobenzonitrile 2450-71-7, Propargylamine 3460-18-2, 2,5-Dibromo-1-nitrobenzene 3473-63-0, Formamidine acetate 4971-56-6, Tetronic acid 5382-16-1, 4-Hydroxypiperidine 5460-70-8, 1,3-Diethoxyacetone 23418-85-1 24424-99-5, Di-tert-butyl dicarbonate

29943-42-8, 4-Oxotetrahydropyran 35161-71-8, N-Methylpropargylamine
38346-95-1 53449-14-2 53449-15-3 69088-96-6 72547-44-5
79099-07-3, tert-Butyl 4-oxo-1-piperidinecarboxylate 89642-24-0
179246-15-2 184475-71-6 193001-44-4, 7-Benzyloxy-4-chloro-6-
methoxyquinazoline hydrochloride 230955-75-6 **451494-38-5**
451494-99-8
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(preparation of phenylaminoquinazoline derivs. as inhibitors of tyrosine-specific protein kinase for preparation and/or treatment of cancers, diseases caused by arteriosclerosis, or psoriasis)

IT 5551-12-2P, 4-Bromo-2-nitrobenzaldehyde 5799-76-8P 7031-23-4P,
3-Methylthiopropionyl chloride 7223-44-1P 7471-07-0P 14731-39-6P
20776-50-5P, 4-Bromoanthranilic acid 45813-02-3P 79603-03-5P,
4-Bromo-2-nitrobenzonitrile 91251-72-8P 99277-71-1P,
4-Bromo-2-nitrobenzoic acid 112253-70-0P, 4-Bromoanthranilamide
147539-53-5P 169194-73-4P 169194-80-3P **179552-73-9P**
194851-16-6P 240400-96-8P 388121-83-3P 423162-80-5P 451492-98-1P
451493-23-5P 451493-24-6P 451493-26-8P 451493-27-9P 451493-62-2P
451494-17-0P 451494-22-7P 451494-23-8P 451494-26-1P 451494-30-7P
451494-31-8P **451494-33-0P** 451494-34-1P 451494-35-2P
451494-36-3P 451494-39-6P 451494-40-9P 451494-41-0P
451494-42-1P 451494-43-2P 451494-44-3P 451494-45-4P 451494-46-5P
451494-47-6P 451494-48-7P 451494-49-8P 451494-50-1P 451494-51-2P
451494-52-3P 451494-53-4P 451494-54-5P 451494-55-6P 451494-56-7P
451494-57-8P 451494-58-9P 451494-59-0P 451494-60-3P 451494-61-4P
451494-62-5P 451494-63-6P 451494-64-7P 451494-65-8P 451494-66-9P
451494-67-0P 451494-68-1P 451494-69-2P 451494-70-5P 451494-71-6P
451494-72-7P 451494-73-8P 451494-74-9P 451494-75-0P 451494-76-1P
451494-77-2P 451494-78-3P 451494-79-4P 451494-80-7P 451494-81-8P
451494-82-9P 451494-83-0P 451494-84-1P 451494-85-2P 451494-86-3P
451494-87-4P 451494-88-5P 451494-89-6P 451494-90-9P 451494-91-0P
451494-92-1P 451494-93-2P 451494-94-3P 451494-95-4P 451494-96-5P
451494-97-6P **451495-00-4P** 451495-02-6P 451495-03-7P
451495-04-8P 451495-05-9P 451495-06-0P 451495-07-1P 451495-08-2P
451495-09-3P 451495-10-6P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(preparation of phenylaminoquinazoline derivs. as inhibitors of tyrosine-specific protein kinase for preparation and/or treatment of cancers, diseases caused by arteriosclerosis, or psoriasis)

IT **451494-21-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of phenylaminoquinazoline derivs. as inhibitors of tyrosine-specific protein kinase for preparation and/or treatment of cancers, diseases caused by arteriosclerosis, or psoriasis)

RN 451494-21-6 CAPLUS
CN 1-Piperazinebutanamide, N-[3-[4-[(3-chloro-4-fluorophenyl)amino]-6-[(1-oxo-2-propenyl)amino]-7-quinazolinyl]-1,1-dimethyl-2-propynyl]-N,4-dimethyl-γ-oxo- (9CI) (CA INDEX NAME)



IT **451494-38-5**
RL: **RCT (Reactant)**; **RACT (Reactant or reagent)**
(preparation of phenylaminoquinazoline derivs. as inhibitors of tyrosine-specific protein kinase for preparation and/or treatment of cancers, diseases caused by arteriosclerosis, or psoriasis)
RN 451494-38-5 CAPLUS
CN 4,6-Quinazolinediamine, 7-bromo-N4-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT **179552-73-9P 451494-33-0P 451494-36-3P**
451495-00-4P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(preparation of phenylaminoquinazoline derivs. as inhibitors of tyrosine-specific protein kinase for preparation and/or treatment of cancers, diseases caused by arteriosclerosis, or psoriasis)
RN 179552-73-9 CAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-chloro-4-fluorophenyl)-6-nitro- (9CI) (CA INDEX NAME)



RN 451494-33-0 CAPLUS
CN 4-Quinazolinamine, 7-bromo-N-(3-chloro-4-fluorophenyl)-6-nitro- (9CI) (CA INDEX NAME)



RN 451494-36-3 CAPLUS
CN 4-Quinazolinamine, 7-bromo-N-(3-chloro-4-fluorophenyl)-6-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 451495-00-4 CAPLUS
CN 4,7-Quinazolinediamine, 6-bromo-N4-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:935582 CAPLUS
DOCUMENT NUMBER: 136:69816
TITLE: Preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth
INVENTOR(S): Kath, John Charles; Bhattacharya, Samit Kumar; Morris, Joel
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098277	A2	20011227	WO 2001-IB1046	20010614
WO 2001098277	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413424	AA	20011227	CA 2001-2413424	20010614
EP 1292591	A2	20030319	EP 2001-938484	20010614
EP 1292591	B1	20050202		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011548	A	20030506	BR 2001-11548	20010614
JP 2004501139	T2	20040115	JP 2002-504233	20010614
EE 200200710	A	20040615	EE 2002-710	20010614

NZ 522568	A	20041224	NZ 2001-522568		20010614
AT 288431	E	20050215	AT 2001-938484		20010614
PT 1292591	T	20050630	PT 2001-938484		20010614
ES 2236240	T3	20050716	ES 2001-1938484		20010614
US 2002169165	A1	20021114	US 2001-883752		20010618
US 6890924	B2	20050510			
BG 107269	A	20030630	BG 2002-107269		20021112
ZA 2002010231	A	20040212	ZA 2002-10231		20021218
NO 2002006166	A	20021220	NO 2002-6166		20021220
US 2005159435	A1	20050721	US 2005-79648		20050314
PRIORITY APPLN. INFO.:			US 2000-213136P	P	20000622
			WO 2001-IB1046	W	20010614
			US 2001-883752	A3	20010618

OTHER SOURCE(S): MARPAT 136:69816

GI



I



II

AB The title compds. [I; m = 0-3; p = 0-4; R1, R2 = H, alkyl; R3 = (CR1R2)t(4-10 membered heterocycle); t = 0-5; R4 = piperidin-4-ylethynyl, 3-(morpholin-4-yl)propenyl, 3-substituted-prop-1-ynyl, etc.; R5 = halo, OH, alkyl, etc.; R11 = halo, CN, NO2, etc.] and their pharmaceutically acceptable salts, useful for treating abnormal cell growth in mammals, were prepared Thus, alkylating 4-ethynylpiperidine-1-carboxylic acid tert-Bu ester with 4-chloro-6-iodoquinazoline followed by reacting the resulting 4-(4-chloroquinazolin-6-ylethynyl)-piperidine-1-carboxylic acid tert Bu ester with 3-methyl-4-(pyridin-3-yloxy)-phenylamine afforded II. The exemplified compds. I have IC50 of < 10 μM against erbB2 kinase.

IC ICM C07D239-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT **383430-47-5P** 383430-50-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

IT 383430-46-4P **383430-48-6P 383430-49-7P** 383430-51-1P
383430-52-2P 383430-53-3P 383430-54-4P
383430-55-5P **383430-56-6P 383430-57-7P**
383430-58-8P 383430-59-9P 383430-60-2P
383430-61-3P 383430-62-4P **383430-63-5P**
383430-64-6P 383430-65-7P **383430-66-8P**
383430-67-9P 383430-68-0P 383430-69-1P
383430-70-4P 383430-71-5P **383430-72-6P** 383430-73-7P
383430-74-8P 383430-75-9P 383430-76-0P **383430-77-1P**
383430-78-2P **383430-79-3P** 383430-80-6P **383430-81-7P**
383430-82-8P 383430-83-9P 383430-84-0P 383430-86-2P
383430-87-3P 383430-88-4P **383430-89-5P 383430-90-8P**
383430-91-9P 383430-92-0P **383430-93-1P**
383430-94-2P 383430-95-3P **383430-96-4P** 383430-97-5P
383430-98-6P **383430-99-7P 383431-00-3P**
383431-01-4P 383431-03-6P 383431-04-7P 383431-05-8P
383431-06-9P 383431-07-0P 383431-08-1P **383431-09-2P**
383431-10-5P 383431-11-6P **383431-12-7P** 383431-13-8P
383431-14-9P 383431-16-1P 383431-17-2P 383431-18-3P
383431-19-4P 383431-20-7P **383431-21-8P 383431-22-9P**
383431-23-0P 383431-24-1P 383431-25-2P
383431-26-3P 383431-27-4P 383431-28-5P
383431-30-9P 383431-31-0P 383431-32-1P
383431-33-2P 383431-34-3P **383431-35-4P 383431-36-5P**
383431-37-6P 383431-38-7P 383431-39-8P 383431-40-1P
383431-41-2P 383431-42-3P 383431-43-4P
383431-44-5P 383431-45-6P 383431-47-8P
383431-48-9P 383431-49-0P 383431-50-3P 383431-51-4P
383431-52-5P 383431-53-6P 383431-54-7P
383431-56-9P 383431-57-0P 383431-58-1P
383431-59-2P 383431-60-5P 383431-61-6P
383431-62-7P 383431-63-8P **383431-64-9P 383431-65-0P**
383431-66-1P 383431-67-2P 383431-68-3P 383431-70-7P
383431-71-8P 383431-72-9P 383431-73-0P 383431-74-1P
383431-75-2P 383431-76-3P 383431-77-4P 383431-78-5P
383431-79-6P 383431-80-9P 383431-81-0P
383431-82-1P 383431-83-2P 383431-84-3P
383431-86-5P 383431-87-6P 383431-88-7P
383431-89-8P 383431-90-1P **383431-91-2P 383431-92-3P**
383431-93-4P 383431-94-5P 383431-95-6P
383431-96-7P 383431-97-8P 383431-99-0P
383432-00-6P **383432-01-7P 383432-02-8P**
383432-03-9P 383432-04-0P 383432-05-1P
383432-06-2P 383432-07-3P 383432-08-4P
383432-09-5P 383432-11-9P 383432-12-0P
383432-13-1P 383432-14-2P 383432-15-3P
383432-16-4P 383432-17-5P 383432-18-6P
383432-19-7P 383432-20-0P 383432-21-1P
383432-23-3P 383432-24-4P 383432-25-5P 383432-26-6P
383432-27-7P **383432-28-8P 383432-29-9P**
383432-30-2P 383432-31-3P **383432-32-4P**
383432-33-5P 383432-34-6P 383432-35-7P
383432-36-8P 383432-38-0P 383432-39-1P
383432-40-4P 383432-41-5P 383432-42-6P

383432-43-7P **383432-44-8P** **383432-45-9P**
383432-46-0P **383432-47-1P** **383432-48-2P**
383432-49-3P **383432-50-6P** **383432-51-7P**
383432-53-9P **383432-54-0P** **383432-55-1P**
383432-56-2P 383432-57-3P **383432-58-4P**
383432-59-5P **383432-60-8P** **383432-61-9P**
383432-62-0P **383432-63-1P** **383432-64-2P**
383432-65-3P **383432-66-4P** **383432-67-5P**
383432-68-6P **383432-70-0P** **383432-71-1P**
383432-72-2P 383432-73-3P **383432-74-4P**
383432-75-5P **383432-76-6P** 383432-77-7P 383432-78-8P
383432-79-9P **383432-80-2P** **383432-81-3P**
383432-82-4P **383432-84-6P** **383432-85-7P**
383432-86-8P **383432-87-9P** **383432-88-0P**
383432-89-1P **383432-90-4P** **383432-91-5P**
383432-92-6P 383432-93-7P 383432-94-8P **383432-95-9P**
383432-96-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation);**
USES (Uses)
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

IT **383432-97-1P** 383432-99-3P 383433-00-9P 383433-01-0P
383433-02-1P **383433-03-2P** **383433-04-3P**
383433-05-4P **383433-06-5P** **383433-07-6P**
383433-08-7P **383433-09-8P** **383433-10-1P**
383433-12-3P **383433-13-4P** **383433-14-5P**
383433-15-6P **383433-16-7P** **383433-17-8P**
383433-18-9P **383433-19-0P** **383433-21-4P**
383433-22-5P **383433-23-6P** **383433-24-7P**
383433-25-8P **383433-26-9P** **383433-27-0P**
383433-28-1P **383433-29-2P** **383433-30-5P**
383433-31-6P **383433-32-7P** **383433-33-8P**
383433-35-0P **383433-36-1P** **383433-37-2P**
383433-38-3P **383433-39-4P** **383433-40-7P**
383433-41-8P **383433-42-9P** **383433-43-0P**
383433-45-2P **383433-46-3P** **383433-47-4P**
383433-48-5P **383433-49-6P** **383433-50-9P**
383433-51-0P **383433-52-1P** **383433-53-2P**
383433-54-3P **383433-55-4P** **383433-56-5P**
383433-57-6P 383433-58-7P **383433-59-8P** **383433-61-2P**
383433-62-3P **383433-63-4P** **383433-64-5P**
383433-65-6P 383433-66-7P **383433-67-8P**
383433-68-9P **383433-69-0P** **383433-70-3P**
383433-71-4P **383433-72-5P** **383433-73-6P**
383433-74-7P **383433-75-8P** **383433-76-9P**
383433-77-0P **383433-78-1P** **383433-79-2P**
383433-80-5P **383433-81-6P** **383433-82-7P**
383433-84-9P 383433-85-0P 383433-86-1P **383433-87-2P**
383433-88-3P **383433-89-4P** **383433-90-7P**
383433-91-8P **383433-93-0P** **383433-94-1P**
383433-95-2P 383433-96-3P **383433-97-4P**
383433-98-5P **383433-99-6P** **383434-00-2P**
383434-01-3P **383434-02-4P** **383434-03-5P**
383434-04-6P **383434-06-8P** **383434-07-9P**
383434-08-0P **383434-09-1P** **383434-10-4P**
383434-11-5P **383434-12-6P** **383434-13-7P**
383434-14-8P **383434-15-9P** **383434-17-1P**
383434-18-2P **383434-19-3P** **383434-20-6P**

383434-21-7P 383434-22-8P **383434-23-9P 383434-24-0P**
383434-25-1P 383434-27-3P 383434-28-4P
383434-29-5P 383434-30-8P 383434-31-9P
383434-32-0P **383434-33-1P** 383434-34-2P **383434-35-3P**
383434-36-4P 383434-37-5P 383434-38-6P
383434-40-0P 383434-41-1P 383434-42-2P **383434-43-3P**
383434-44-4P 383434-45-5P 383434-46-6P
383434-47-7P **383434-48-8P 383434-49-9P**
383434-50-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

IT 287193-30-0P 383434-51-3P 383434-53-5P **383434-54-6P**
383434-55-7P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

IT **383430-47-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

RN 383430-47-5 CAPLUS
CN Acetamide, 2-chloro-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



IT **383430-48-6P 383430-49-7P 383430-52-2P**
383430-53-3P 383430-54-4P 383430-56-6P
383430-57-7P 383430-58-8P 383430-59-9P
383430-60-2P 383430-61-3P 383430-63-5P
383430-64-6P 383430-66-8P 383430-67-9P
383430-68-0P 383430-69-1P 383430-70-4P
383430-72-6P 383430-77-1P 383430-79-3P
383430-81-7P 383430-82-8P 383430-89-5P
383430-90-8P 383430-91-9P 383430-93-1P

383430-94-2P 383430-96-4P 383430-99-7P
383431-00-3P 383431-01-4P 383431-09-2P
383431-12-7P 383431-14-9P 383431-16-1P
383431-21-8P 383431-22-9P 383431-23-0P
383431-24-1P 383431-25-2P 383431-26-3P
383431-27-4P 383431-28-5P 383431-30-9P
383431-31-0P 383431-32-1P 383431-35-4P
383431-36-5P 383431-37-6P 383431-38-7P
383431-41-2P 383431-42-3P 383431-43-4P
383431-44-5P 383431-45-6P 383431-47-8P
383431-48-9P 383431-52-5P 383431-53-6P
383431-54-7P 383431-56-9P 383431-57-0P
383431-58-1P 383431-59-2P 383431-60-5P
383431-61-6P 383431-64-9P 383431-65-0P
383431-66-1P 383431-67-2P 383431-71-8P
383431-72-9P 383431-79-6P 383431-80-9P
383431-81-0P 383431-82-1P 383431-83-2P
383431-84-3P 383431-86-5P 383431-87-6P
383431-88-7P 383431-91-2P 383431-92-3P
383431-93-4P 383431-94-5P 383431-95-6P
383431-96-7P 383431-97-8P 383431-99-0P
383432-01-7P 383432-02-8P 383432-03-9P
383432-04-0P 383432-05-1P 383432-06-2P
383432-07-3P 383432-08-4P 383432-09-5P
383432-11-9P 383432-12-0P 383432-13-1P
383432-14-2P 383432-15-3P 383432-16-4P
383432-17-5P 383432-18-6P 383432-19-7P
383432-20-0P 383432-21-1P 383432-23-3P
383432-24-4P 383432-28-8P 383432-29-9P
383432-30-2P 383432-32-4P 383432-33-5P
383432-34-6P 383432-35-7P 383432-36-8P
383432-38-0P 383432-39-1P 383432-40-4P
383432-41-5P 383432-42-6P 383432-43-7P
383432-44-8P 383432-45-9P 383432-46-0P
383432-47-1P 383432-48-2P 383432-49-3P
383432-50-6P 383432-51-7P 383432-53-9P
383432-54-0P 383432-55-1P 383432-56-2P
383432-58-4P 383432-59-5P 383432-60-8P
383432-61-9P 383432-62-0P 383432-63-1P
383432-64-2P 383432-65-3P 383432-66-4P
383432-67-5P 383432-68-6P 383432-70-0P
383432-71-1P 383432-72-2P 383432-74-4P
383432-75-5P 383432-76-6P 383432-79-9P
383432-80-2P 383432-81-3P 383432-82-4P
383432-84-6P 383432-85-7P 383432-86-8P
383432-87-9P 383432-88-0P 383432-89-1P
383432-90-4P 383432-91-5P 383432-92-6P
383432-95-9P 383432-97-1P 383433-02-1P
383433-03-2P 383433-04-3P 383433-05-4P
383433-06-5P 383433-07-6P 383433-08-7P
383433-09-8P 383433-10-1P 383433-12-3P
383433-13-4P 383433-14-5P 383433-15-6P
383433-16-7P 383433-17-8P 383433-18-9P
383433-19-0P 383433-21-4P 383433-22-5P
383433-23-6P 383433-24-7P 383433-25-8P
383433-26-9P 383433-27-0P 383433-28-1P
383433-29-2P 383433-30-5P 383433-31-6P
383433-32-7P 383433-33-8P 383433-35-0P
383433-36-1P 383433-37-2P 383433-38-3P

383433-39-4P 383433-40-7P 383433-41-8P
383433-42-9P 383433-43-0P 383433-45-2P
383433-46-3P 383433-47-4P 383433-48-5P
383433-49-6P 383433-50-9P 383433-51-0P
383433-52-1P 383433-53-2P 383433-54-3P
383433-55-4P 383433-56-5P 383433-59-8P
383433-61-2P 383433-62-3P 383433-63-4P
383433-64-5P 383433-65-6P 383433-67-8P
383433-68-9P 383433-69-0P 383433-70-3P
383433-71-4P 383433-72-5P 383433-73-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

RN 383430-48-6 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 383430-49-7 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 383430-52-2 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383430-53-3 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(methoxymethyl)-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383430-54-4 CAPLUS
CN Propanamide, 2-hydroxy-2-methyl-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383430-56-6 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-cyclopropyl- (9CI) (CA INDEX NAME)



RN 383430-57-7 CAPLUS
CN Acetamide, N-[3-[7-chloro-4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-58-8 CAPLUS
CN Acetamide, N-[3-[7-chloro-4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-59-9 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-6-(hydroxymethyl)-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





RN 383430-60-2 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(2-fluoroethyl)- (9CI) (CA INDEX NAME)



RN 383430-61-3 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 383430-63-5 CAPLUS
CN Acetamide, 2-[(2-hydroxyethyl)thio]-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-64-6 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-[(2-hydroxyethyl)thio]- (9CI) (CA INDEX NAME)



RN 383430-66-8 CAPLUS
CN Acetamide, 2-cyano-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-67-9 CAPLUS
CN Butanamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-68-0 CAPLUS
CN Pentanamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-69-1 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-70-4 CAPLUS
CN Acetamide, N-[4-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-3-butynyl]- (9CI) (CA INDEX NAME)



RN 383430-72-6 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 383430-77-1 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383430-79-3 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-81-7 CAPLUS
CN Acetamide, 2-(methylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-82-8 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-89-5 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methoxy-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-90-8 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383430-91-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-fluoro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383430-93-1 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-94-2 CAPLUS
CN Propanamide, 2-methyl-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-96-4 CAPLUS
CN Acetamide, 2-(diethylamino)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383430-99-7 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(2-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-00-3 CAPLUS
CN Acetamide, 2-(2-methoxyethoxy)-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-01-4 CAPLUS
CN 2-Furancarboxamide, tetrahydro-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-09-2 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-12-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-3-butynyl]- (9CI) (CA INDEX NAME)



RN 383431-14-9 CAPLUS
CN Acetamide, N-[3-[4-[[4-[(2-chloro-3-pyridinyl)oxy]-3-methylphenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383431-16-1 CAPLUS
CN Acetamide, N-[4-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-3-butynyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 383431-21-8 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-(4-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-22-9 CAPLUS
CN Acetamide, 2,2-difluoro-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-23-0 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2,2-difluoro- (9CI) (CA INDEX NAME)



RN 383431-24-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383431-25-2 CAPLUS
CN 3-Furancarboxamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 383431-26-3 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-3-butynyl]- (9CI) (CA INDEX NAME)



RN 383431-27-4 CAPLUS
CN Acetamide, N-[4-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-3-butynyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 383431-28-5 CAPLUS
CN Urea, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 383431-30-9 CAPLUS
CN Urea, N-cyclohexyl-N'-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-31-0 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-cyclohexyl- (9CI) (CA INDEX NAME)



RN 383431-32-1 CAPLUS
CN Acetamide, 2-hydroxy-N-[4-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-3-butynyl]- (9CI) (CA INDEX NAME)



RN 383431-35-4 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 383431-36-5 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 383431-37-6 CAPLUS
CN Carbamothioic acid, [3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, S-methyl ester (9CI) (CA INDEX NAME)



RN 383431-38-7 CAPLUS
CN Carbamothioic acid, [3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, S-methyl ester (9CI) (CA INDEX NAME)



RN 383431-41-2 CAPLUS
CN Acetamide, N-[3-[4-[[4-[(2-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-42-3 CAPLUS
CN Propanamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 383431-43-4 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 383431-44-5 CAPLUS
CN Propanoic acid, 3-[[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 383431-45-6 CAPLUS
CN Propanoic acid, 3-[[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 383431-47-8 CAPLUS
CN Acetamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 383431-48-9 CAPLUS
CN Acetamide, N-[1-(hydroxymethyl)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-52-5 CAPLUS
CN Acetamide, N-[1-(hydroxymethyl)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-53-6 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-1-(hydroxymethyl)-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-54-7 CAPLUS
CN Acetamide, 2,2-difluoro-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-56-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 383431-57-0 CAPLUS
CN Acetamide, 2-fluoro-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-58-1 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 383431-59-2 CAPLUS
CN Acetamide, 2-fluoro-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-60-5 CAPLUS
CN Acetamide, N-[3-[4-[[3-ethynyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383431-61-6 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[4-[(2-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-64-9 CAPLUS
CN Acetamide, N-[3-[4-[[4-[(2-chloro-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383431-65-0 CAPLUS
CN Acetamide, N-[3-[4-[[4-[(2-chloro-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-66-1 CAPLUS
CN Acetamide, N-[3-[4-[[3-ethynyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-67-2 CAPLUS
CN Urea, N-(2-chloroethyl)-N'-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-71-8 CAPLUS
CN Acetamide, N-[3-[4-[[3-fluoro-4-[(2-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-72-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-79-6 CAPLUS
CN Acetamide, 2-hydroxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-80-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-81-0 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383431-82-1 CAPLUS
CN Acetamide, 2-[(2-hydroxyethyl)thio]-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-83-2 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 383431-84-3 CAPLUS
CN Carbamothioic acid, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, S-methyl ester (9CI) (CA INDEX NAME)



RN 383431-86-5 CAPLUS
CN 3-Furancarboxamide, tetrahydro-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-87-6 CAPLUS
CN Propanamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 383431-88-7 CAPLUS
CN Propanoic acid, 3-[[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 383431-91-2 CAPLUS
CN Acetamide, N-[3-[4-[[4-(2-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-92-3 CAPLUS
CN Acetamide, 2-(methylamino)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-93-4 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-94-5 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-1-(hydroxymethyl)-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383431-95-6 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 383431-96-7 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383431-97-8 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 383431-99-0 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2,2-difluoro- (9CI) (CA INDEX NAME)



RN 383432-01-7 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[4-(2-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-02-8 CAPLUS
CN Urea, N-ethyl-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-03-9 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 383432-04-0 CAPLUS
CN Urea, N-ethyl-N'-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-05-1 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 383432-06-2 CAPLUS
CN Propanamide, 2-hydroxy-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-07-3 CAPLUS
CN Propanamide, N-[3-[4-[[3-methyl-4-[(2-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 383432-08-4 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(2-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-09-5 CAPLUS
CN Propanamide, 2-hydroxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-11-9 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 383432-12-0 CAPLUS
CN 1-Piperazineacetamide, 4-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-13-1 CAPLUS
CN Acetamide, 2-[bis(2-methoxyethyl)amino]-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-14-2 CAPLUS
CN Acetamide, 2-[(2-hydroxyethyl)amino]-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-15-3 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 383432-16-4 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 383432-17-5 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 383432-18-6 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 383432-19-7 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 383432-20-0 CAPLUS
CN Urea, N-(1-methylethyl)-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-21-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-23-3 CAPLUS
CN 4-Morpholineacetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-24-4 CAPLUS
CN 4-Morpholineacetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-28-8 CAPLUS
CN Propanamide, 2-hydroxy-2-methyl-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-29-9 CAPLUS
CN Propanamide, 2-hydroxy-2-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-30-2 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)



RN 383432-32-4 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-[(2,2,2-trifluoroethyl)amino]- (9CI) (CA INDEX NAME)



RN 383432-33-5 CAPLUS
CN Urea, N,N-dimethyl-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-34-6 CAPLUS
CN Urea, N'-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 383432-35-7 CAPLUS
CN Urea, N'-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 383432-36-8 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-38-0 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-39-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-40-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-41-5 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-propyl- (9CI) (CA INDEX NAME)



RN 383432-42-6 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 383432-43-7 CAPLUS
CN Propanamide, 2-hydroxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383432-44-8 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 383432-45-9 CAPLUS
CN 2-Azetidinecarboxamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-46-0 CAPLUS
CN 2-Azetidinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-47-1 CAPLUS
CN 2-Azetidinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-48-2 CAPLUS
CN Cyclopropanecarboxamide, 1-hydroxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-49-3 CAPLUS
CN Propanamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-50-6 CAPLUS
CN Butanamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-51-7 CAPLUS
CN Propanamide, 2-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-53-9 CAPLUS
CN Acetamide, 2-ethoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-54-0 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 383432-55-1 CAPLUS
CN Cyclopropanecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-56-2 CAPLUS
CN Cyclobutanecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-58-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-59-5 CAPLUS
CN Acetamide, N-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-60-8 CAPLUS
CN Acetamide, 2-methoxy-N-[1-methyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-61-9 CAPLUS
CN Acetamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-62-0 CAPLUS
CN Propanamide, 2-hydroxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383432-63-1 CAPLUS
CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-64-2 CAPLUS
CN Propanamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-65-3 CAPLUS
CN Acetamide, 2-ethoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-66-4 CAPLUS
CN Propanamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-67-5 CAPLUS
CN Acetamide, 2-fluoro-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-68-6 CAPLUS
CN Acetamide, 2-methoxy-N-[1-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]ethynyl]cyclobutyl]- (9CI) (CA INDEX NAME)



RN 383432-70-0 CAPLUS
CN Acetamide, N-[1-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]ethynyl]cyclobutyl]- (9CI) (CA INDEX NAME)



RN 383432-71-1 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-72-2 CAPLUS
CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383432-74-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(methoxymethyl)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-75-5 CAPLUS
CN 1-Piperazinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-76-6 CAPLUS
CN Urea, N'-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N-ethyl-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 383432-79-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 383432-80-2 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 383432-81-3 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-[(2-hydroxyethyl)thio]- (9CI) (CA INDEX NAME)



RN 383432-82-4 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 383432-84-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383432-85-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383432-86-8 CAPLUS
CN Acetamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 383432-87-9 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 383432-88-0 CAPLUS
CN 3-Furancarboxamide, tetrahydro-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-89-1 CAPLUS
CN Acetamide, 2-hydroxy-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-90-4 CAPLUS
CN Acetamide, 2-ethoxy-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-91-5 CAPLUS
CN Cyclobutanecarboxamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-92-6 CAPLUS
CN Cyclopropanecarboxamide, N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383432-95-9 CAPLUS
CN Acetamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383432-97-1 CAPLUS
CN Acetamide, 2-methoxy-N-[1-methyl-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-02-1 CAPLUS
CN Urea, N-(2-methoxyethyl)-N-methyl-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-03-2 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(hydroxymethyl)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-04-3 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-05-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2,5-dimethyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-06-5 CAPLUS
CN Urea, N-methyl-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 383433-07-6 CAPLUS
CN Acetamide, N-[1-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]ethynyl]cyclopropyl]- (9CI) (CA INDEX NAME)



RN 383433-08-7 CAPLUS
CN Acetamide, 2-methoxy-N-[1-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]ethynyl]cyclopropyl]- (9CI) (CA INDEX NAME)



RN 383433-09-8 CAPLUS
CN Propanamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-10-1 CAPLUS
CN Propanamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-12-3 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-13-4 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-ethoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-14-5 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383433-15-6 CAPLUS
CN Cyclobutanecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-16-7 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-17-8 CAPLUS
CN Cyclopropanecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-18-9 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 383433-19-0 CAPLUS
CN Propanamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383433-21-4 CAPLUS
CN Propanamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-22-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-5-oxo-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383433-23-6 CAPLUS
CN Cyclopropanecarboxamide, 1-hydroxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-24-7 CAPLUS
CN Propanamide, 2-hydroxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-25-8 CAPLUS
CN Propanamide, 2-hydroxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-26-9 CAPLUS
CN Acetamide, 2-hydroxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-27-0 CAPLUS
CN Urea, N-(cyanomethyl)-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-28-1 CAPLUS
CN Urea, N-cyclobutyl-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-29-2 CAPLUS
CN Urea, trimethyl[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-30-5 CAPLUS
CN Urea, [3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]trimethyl- (9CI) (CA INDEX NAME)



RN 383433-31-6 CAPLUS
CN Urea, N-ethyl-N-(2-hydroxyethyl)-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-32-7 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-(dimethylamino)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-33-8 CAPLUS
CN 4-Morpholinecarboxamide, N-[1-methyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-35-0 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-amino-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 383433-36-1 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-(hydroxymethyl)-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 383433-37-2 CAPLUS
CN Urea, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-38-3 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-39-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-40-7 CAPLUS
CN Urea, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 383433-41-8 CAPLUS
CN 4-Morpholinecarboxamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-42-9 CAPLUS
CN Urea, N,N'-dimethyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-43-0 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-1,1-dimethyl-2-propynyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 383433-45-2 CAPLUS
CN Acetamide, N-[1,1-dimethyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 383433-46-3 CAPLUS
CN Urea, N,N-diethyl-N'-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-47-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-48-5 CAPLUS
CN Urea, N-ethyl-N'-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-49-6 CAPLUS
CN 4-Morpholinecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-50-9 CAPLUS
CN Urea, N-ethyl-N-(2-hydroxyethyl)-N'-[1-methyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-51-0 CAPLUS
CN Urea, N-ethyl-N'-[1-methyl-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-52-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX

NAME)



RN 383433-53-2 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-cyano- (9CI) (CA INDEX NAME)



RN 383433-54-3 CAPLUS
CN Acetamide, 2-cyano-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-55-4 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-(methylthio)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-56-5 CAPLUS
CN 2-Furancarboxamide, tetrahydro-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-5-oxo-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-59-8 CAPLUS
CN Propanamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-61-2 CAPLUS
CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-1-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-62-3 CAPLUS
CN Propanamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-hydroxy-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-63-4 CAPLUS
CN Propanamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-64-5 CAPLUS
CN Propanamide, 2-amino-N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383433-65-6 CAPLUS
CN Propanamide, 2-amino-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383433-67-8 CAPLUS
CN Propanamide, 3,3,3-trifluoro-2-hydroxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-68-9 CAPLUS
CN Butanamide, 2-hydroxy-3-methyl-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-69-0 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 383433-70-3 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 383433-71-4 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1,2-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 383433-72-5 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1,1-dimethylpropyl)- (9CI) (CA INDEX NAME)



RN 383433-73-6 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-[1-(hydroxymethyl)propyl]- (9CI) (CA INDEX NAME)



IT **383433-74-7P 383433-75-8P 383433-76-9P**
383433-77-0P 383433-78-1P 383433-79-2P
383433-80-5P 383433-81-6P 383433-82-7P
383433-84-9P 383433-87-2P 383433-88-3P
383433-89-4P 383433-90-7P 383433-91-8P
383433-93-0P 383433-94-1P 383433-95-2P
383433-97-4P 383433-98-5P 383433-99-6P
383434-00-2P 383434-01-3P 383434-02-4P
383434-03-5P 383434-04-6P 383434-06-8P
383434-07-9P 383434-08-0P 383434-09-1P
383434-10-4P 383434-11-5P 383434-12-6P

383434-13-7P 383434-14-8P 383434-15-9P
383434-17-1P 383434-18-2P 383434-19-3P
383434-20-6P 383434-23-9P 383434-24-0P
383434-25-1P 383434-27-3P 383434-28-4P
383434-29-5P 383434-30-8P 383434-31-9P
383434-33-1P 383434-35-3P 383434-36-4P
383434-37-5P 383434-38-6P 383434-40-0P
383434-43-3P 383434-44-4P 383434-45-5P
383434-46-6P 383434-48-8P 383434-49-9P
383434-50-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)

RN 383433-74-7 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 383433-75-8 CAPLUS
CN Urea, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 383433-76-9 CAPLUS
CN Urea, N-(1,1-dimethylpropyl)-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-77-0 CAPLUS
CN Urea, N-[1-(hydroxymethyl)propyl]-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-78-1 CAPLUS
CN Urea, N-(1-ethylpropyl)-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-79-2 CAPLUS
CN Urea, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N'-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 383433-80-5 CAPLUS
CN Urea, N-(1,2-dimethylpropyl)-N'-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-81-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383433-82-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-84-9 CAPLUS
CN Acetamide, 2-(1-methylethoxy)-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-87-2 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-88-3 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-89-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-90-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-91-8 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-93-0 CAPLUS
CN 2-Furancarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]tetrahydro-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-94-1 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-(cyclopropylmethoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-95-2 CAPLUS
CN Butanamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-2-hydroxy-3-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383433-97-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(hydroxymethyl)-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-98-5 CAPLUS
CN 1-Pyrrolidinecarboxamide, 2-(hydroxymethyl)-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383433-99-6 CAPLUS
CN Acetamide, 2-(cyclopropylmethoxy)-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-00-2 CAPLUS
CN Urea, N-(1-methylethyl)-N'-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-01-3 CAPLUS
CN 1-Azetidinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-02-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-03-5 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[7-methoxy-4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-04-6 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-7-methoxy-6-quinazolinyl]-2-propynyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 383434-06-8 CAPLUS
CN Urea, N'-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 383434-07-9 CAPLUS
CN Acetamide, N-[3-[7-methoxy-4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-08-0 CAPLUS
CN Acetamide, N-[3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-7-methoxy-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-09-1 CAPLUS
CN Urea, N'-[3-[7-methoxy-4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 383434-10-4 CAPLUS
CN 1-Piperidinecarboxamide, 2-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-11-5 CAPLUS
CN 2-Azetidinecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383434-12-6 CAPLUS
CN Cyclopropanecarboxamide, 1-amino-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-13-7 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-14-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383434-15-9 CAPLUS
CN Propanamide, 2-amino-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383434-17-1 CAPLUS
CN Propanamide, 2-amino-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 383434-18-2 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-19-3 CAPLUS
CN Urea, N'-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-20-6 CAPLUS
CN 2-Pyridinecarboxamide, N-[(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-23-9 CAPLUS

CN Cyclopropanecarboxamide, N-[(2Z)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-24-0 CAPLUS
CN Acetamide, N-[(2Z)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-25-1 CAPLUS
CN Propanamide, 2-methyl-N-[(2Z)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-27-3 CAPLUS
CN Carbamic acid, [3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383434-28-4 CAPLUS
CN Carbamic acid, [3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 383434-29-5 CAPLUS
CN Carbamic acid, [3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 383434-30-8 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-31-9 CAPLUS
CN 2-Pyridinecarboxamide, 3-methyl-N-[3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)



RN 383434-33-1 CAPLUS
CN Acetamide, 2-fluoro-N-[3-[4-[[3-methyl-4-[(2-methyl-5-pyrimidinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-35-3 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-[(2-methyl-5-pyrimidinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-36-4 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(2-methyl-5-pyrimidinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-37-5 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[[3-methyl-4-(5-pyrimidinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-38-6 CAPLUS
CN Propanamide, 2-methyl-N-[3-[4-[[3-methyl-4-(5-pyrimidinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-40-0 CAPLUS
CN 5-Isoxazolecarboxamide, 3-methyl-N-[3-[4-[[3-methyl-4-(5-pyrimidinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-43-3 CAPLUS
CN Acetamide, 2-methoxy-N-methyl-N-[3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 383434-44-4 CAPLUS
CN Acetamide, N-[(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-45-5 CAPLUS
CN Acetamide, 2-methoxy-N-[(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-46-6 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-48-8 CAPLUS
CN Cyclopropanecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-49-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-50-2 CAPLUS
CN Urea, N-ethyl-N'-[(2E)-3-[4-[[3-methyl-4-(3-pyridinyloxy)phenyl]amino]-6-quinazolinyl]-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **383434-54-6P 383434-55-7P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP (Preparation)**; **RACT (Reactant or reagent)**
(preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth)
RN 383434-54-6 CAPLUS
CN Carbamic acid, [(2E)-3-[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 383434-55-7 CAPLUS
CN 4-Quinazolinamine, 6-[(1Z)-3-amino-1-propenyl]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L40 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:535121 CAPLUS
DOCUMENT NUMBER: 133:150572
TITLE: Preparation of substituted bicyclic derivatives useful as anticancer agents
INVENTOR(S): Kath, John Charles; Tom, Norma Jacqueline; Liu, Zhengyu; Cox, Eric David; Bhattacharya, Samit Kumar; Morris, Joel
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044728	A1	20000803	WO 1999-IB1934	19991206

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

TW 519541	B	20030201	TW 1999-88120466	19991123
CA 2358998	AA	20000803	CA 1999-2358998	19991206
EP 1147093	A1	20011024	EP 1999-956281	19991206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916980	A	20011106	BR 1999-16980	19991206
TR 200102136	T2	20011121	TR 2001-200102136	19991206
EE 200100393	A	20021015	EE 2001-393	19991206
JP 2002535391	T2	20021022	JP 2000-595984	19991206
NZ 511707	A	20040130	NZ 1999-511707	19991206
AU 775163	B2	20040722	AU 2000-12916	19991206
US 6284764	B1	20010904	US 2000-488350	20000120
US 2001034351	A1	20011025	US 2001-834259	20010412
US 6541481	B2	20030401		
ZA 2001005867	A	20020717	ZA 2001-5867	20010717
HR 2001000542	A1	20020831	HR 2001-542	20010718
NO 2001003671	A	20010926	NO 2001-3671	20010726
BG 105842	A	20020430	BG 2001-105842	20010824
HK 1043795	A1	20050812	HK 2002-105471	20020724
US 2003186995	A1	20031002	US 2003-349475	20030121
JP 2005002125	A2	20050106	JP 2004-216138	20040723

PRIORITY APPLN. INFO.:

US 1999-117346P	P	19990127
JP 2000-595984	A3	19991206
WO 1999-IB1934	W	19991206
US 2000-488350	A3	20000120
US 2001-834259	A1	20010412

OTHER SOURCE(S): MARPAT 133:150572

GI



I II

AB The title compds. [I; X = N, CH; A = (un)substituted fused 5-7 membered ring optionally containing 1-4 heteroatoms selected from NR1, O, S(O)j (wherein j = 0-2); R1, R2 = H, alkyl; R3 = (CR1R2)mR8 (m = 0-1; R8 = (CR1R2)taryl, (CR1R2)theterocyclyl; t = 0-5); R1 and R3 are taken together to form (un)substituted indol-1-yl, indolin-1-yl; R4 = (CR1R2)mC.tplbond.C(CR1R2)tR9 (m = 0-3; t = 0-5; R9 = a non-aromatic mono-cyclic ring, a fused or bridged bicyclic ring, etc.), C:NOR12 (R12 = H, alkyl, CO2alkyl, etc.), X1R12 (X1 = a divalent group derived from azetidine, oxetane or carbocyclic group), etc.] and their pharmaceutically acceptable salts, useful in treating abnormal cell growth in mammals, were prepared Thus, treatment of (3-methyl-4-phenoxyphenyl)-(6-piperidin-3-

ylethynylquinazolin-4-yl)amine with propionaldehyde in MeOH/H2O at pH = 5 followed by addition of NaBH3CN afforded quinazoline II.HCl. Compds. I are effective at 1-35 mg/kg/day.

IC ICM C07D239-94
ICS C07D403-06; C07D401-12; C07D403-12; C07D403-04; C07D401-06; C07D401-14; A61K031-517

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 287188-72-1P 287189-02-0P 287189-05-3P 287189-21-3P 287189-25-7P
287192-33-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(preparation of substituted bicyclic derivs. useful as anticancer agents)

IT 287191-12-2P 287191-13-3P 287191-14-4P 287191-15-5P 287191-16-6P
287191-17-7P 287191-18-8P 287191-19-9P 287191-20-2P 287191-21-3P
287191-22-4P 287191-23-5P 287191-24-6P 287191-25-7P 287191-26-8P
287191-27-9P 287191-28-0P 287191-29-1P 287191-30-4P 287191-31-5P
287191-32-6P 287191-33-7P 287191-34-8P 287191-35-9P 287191-36-0P
287191-37-1P 287191-38-2P 287191-39-3P 287191-40-6P 287191-41-7P
287191-42-8P 287191-43-9P 287191-44-0P 287191-45-1P 287191-46-2P
287191-47-3P 287191-48-4P 287191-49-5P 287191-50-8P 287191-52-0P
287191-53-1P 287191-54-2P 287191-55-3P 287191-56-4P 287191-57-5P
287191-58-6P 287191-59-7P 287191-60-0P 287191-61-1P 287191-62-2P
287191-63-3P 287191-64-4P 287191-65-5P 287191-66-6P 287191-67-7P
287191-68-8P 287191-69-9P 287191-70-2P 287191-71-3P 287191-72-4P
287191-73-5P 287191-74-6P 287191-75-7P 287191-76-8P 287191-77-9P
287191-78-0P 287191-79-1P 287191-80-4P 287191-81-5P 287191-82-6P
287191-83-7P 287191-84-8P 287191-85-9P 287191-86-0P 287191-87-1P
287191-88-2P 287191-89-3P 287191-90-6P 287191-91-7P 287191-92-8P
287191-93-9P 287191-94-0P 287191-95-1P 287191-96-2P 287191-97-3P
287191-98-4P 287191-99-5P 287192-00-1P 287192-01-2P 287192-02-3P
287192-03-4P 287192-04-5P 287192-05-6P 287192-06-7P 287192-07-8P
287192-08-9P 287192-09-0P 287192-10-3P 287192-11-4P 287192-13-6P
287192-14-7P 287192-15-8P 287192-16-9P **287192-17-0P**
287192-18-1P 287192-19-2P 287192-20-5P 287192-21-6P
287192-22-7P 287192-23-8P 287192-24-9P **287192-25-0P**
287192-26-1P 287192-27-2P 287192-28-3P
287192-29-4P 287192-30-7P 287192-31-8P 287192-32-9P
287192-34-1P 287192-35-2P 287192-36-3P
287192-37-4P 287192-38-5P 287192-39-6P 287192-40-9P
287192-41-0P 287192-42-1P 287192-43-2P 287192-44-3P 287192-45-4P
287192-46-5P 287192-47-6P 287192-48-7P 287192-49-8P
287192-50-1P 287192-51-2P **287192-52-3P**
287192-53-4P 287192-54-5P 287192-55-6P 287192-56-7P
287192-57-8P 287192-58-9P **287192-59-0P 287192-60-3P**
287192-61-4P 287192-62-5P 287192-63-6P 287192-64-7P
287192-65-8P 287192-66-9P 287192-67-0P 287192-68-1P 287192-69-2P
287192-70-5P 287192-71-6P 287192-72-7P 287192-73-8P 287399-37-5P
287399-38-6P 287399-40-0P 287399-42-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of substituted bicyclic derivs. useful as anticancer agents)

IT 4187-86-4P, 1-Pentyn-3-ol 7458-03-9P 16064-08-7P 20734-46-7P
57385-16-7P 98556-31-1P 102520-97-8P 109608-77-7P 160127-75-3P
160172-20-3P 171349-95-4P 191284-80-7P 255864-58-5P 275387-76-3P
275387-83-2P 287192-74-9P 287192-75-0P 287192-77-2P 287192-78-3P

287192-80-7P 287192-81-8P 287192-83-0P 287192-85-2P 287192-86-3P
287192-88-5P 287192-89-6P 287192-90-9P 287192-91-0P 287192-92-1P
287192-93-2P 287192-94-3P 287192-95-4P 287192-96-5P 287192-97-6P
287192-98-7P 287192-99-8P 287193-00-4P 287193-01-5P 287193-02-6P
287193-03-7P 287193-04-8P 287193-05-9P 287193-06-0P 287193-07-1P
287193-08-2P 287193-09-3P 287193-10-6P 287193-11-7P 287193-12-8P
287193-13-9P 287193-14-0P **287193-15-1P 287193-16-2P**
287193-17-3P 287193-18-4P 287193-19-5P 287193-20-8P 287193-21-9P
287193-22-0P 287193-23-1P 287193-24-2P 287193-25-3P 287193-26-4P
287193-28-6P 287193-29-7P 287193-30-0P 287193-31-1P 287193-33-3P
287399-44-4P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(preparation of substituted bicyclic derivs. useful as anticancer agents)

IT **287192-33-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; RACT (Reactant or reagent); USES (Uses)
(preparation of substituted bicyclic derivs. useful as anticancer agents)

RN 287192-33-0 CAPLUS
CN Acetamide, 2-chloro-N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



IT **287192-17-0P 287192-18-1P 287192-22-7P**
287192-25-0P 287192-26-1P 287192-27-2P
287192-28-3P 287192-34-1P 287192-35-2P
287192-36-3P 287192-37-4P 287192-50-1P
287192-52-3P 287192-53-4P 287192-59-0P
287192-60-3P 287192-61-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP (Preparation)**; USES (Uses)
(preparation of substituted bicyclic derivs. useful as anticancer agents)

RN 287192-17-0 CAPLUS
CN Acetamide, N-[3-[4-[(4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-18-1 CAPLUS
CN Acetamide, N-[3-[4-[(3-chloro-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-22-7 CAPLUS
CN Propanamide, 2-methyl-N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-25-0 CAPLUS
CN Acetamide, N-methyl-N-[3-[4-[(4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-26-1 CAPLUS
CN Acetamide, N-methyl-N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-27-2 CAPLUS
CN Acetamide, N-[3-[4-[(3-chloro-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 287192-28-3 CAPLUS
CN Propanamide, 2,2-dimethyl-N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-34-1 CAPLUS
CN Cyclopropanecarboxamide, N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-35-2 CAPLUS
CN Propanamide, N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-36-3 CAPLUS
CN Acetamide, 2-methoxy-N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-

quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-37-4 CAPLUS
CN 4-Morpholineacetamide, N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-50-1 CAPLUS
CN Acetamide, N-[1,1-dimethyl-3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 287192-52-3 CAPLUS

CN Acetamide, N-[1,1-dimethyl-3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-53-4 CAPLUS
CN Acetamide, N-[3-[4-[(3-chloro-4-phenoxyphenyl)amino]-6-quinazolinyl]-1,1-dimethyl-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-59-0 CAPLUS
CN Acetamide, N-[3-[4-[(3-chloro-4-phenoxyphenyl)amino]-6-quinazolinyl]-1-methyl-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-60-3 CAPLUS
CN Acetamide, N-[1-methyl-3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



RN 287192-61-4 CAPLUS
CN Acetamide, N-[3-[4-[(3-methyl-4-phenoxyphenyl)amino]-6-quinazolinyl]-2-propynyl]- (9CI) (CA INDEX NAME)



IT **287193-15-1P 287193-16-2P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation); **RACT (Reactant or reagent)**
(preparation of substituted bicyclic derivs. useful as anticancer agents)
RN 287193-15-1 CAPLUS
CN 1H-Indol-5-amine, N-(6-iodo-4-quinazolinyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 287193-16-2 CAPLUS
CN 4-Quinazolinamine, 6-iodo-N-(3-methyl-4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AUTHOR SEARCH in CAPlus


```
=> file caplus
FILE 'CAPLUS' ENTERED AT 16:12:47 ON 20 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 Jan 2006  VOL 144 ISS 5
FILE LAST UPDATED: 19 Jan 2006  (20060119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que L45
L42          51 SEA FILE=CAPLUS ABB=ON  PLU=ON  RIPIN D?/AU
L43          19 SEA FILE=CAPLUS ABB=ON  PLU=ON  VETELINO M?/AU
L44        2406 SEA FILE=CAPLUS ABB=ON  PLU=ON  WEI L?/AU
L45           2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L42 AND L43 AND L44


=> d que L46
L42          51 SEA FILE=CAPLUS ABB=ON  PLU=ON  RIPIN D?/AU
L43          19 SEA FILE=CAPLUS ABB=ON  PLU=ON  VETELINO M?/AU
L44        2406 SEA FILE=CAPLUS ABB=ON  PLU=ON  WEI L?/AU
L46           8 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L42 AND (L43 OR L44)) OR (L43
                AND L44)


=> s L45 or L46
L47           8 L45 OR L46

=> d ibib abs hitind L47 1-8

L47  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:1294039  CAPLUS
DOCUMENT NUMBER:          144:40817
TITLE:                    Preparation of sesquisuccinate complexes of
                          E-2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-
                          yloxy)phenylamino]quinazolin-6-yl}allyl)acetamide
INVENTOR(S):              Johnson, Phillip James; Ripin, David Harold
                          Brown; Rose, Peter Robert; Tickner, Jeanene
                          Elizabeth; Vetelino, Michael Girard
PATENT ASSIGNEE(S):       Pfizer Inc, USA
SOURCE:                   U.S. Pat. Appl. Publ., 11 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
```

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005272752	A1	20051208	US 2005-136775	20050525
WO 2005121124	A1	20051222	WO 2005-IB1533	20050523

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-578001P P 20040607

AB This invention relates to methods of making sesquisuccinate complexes of E-2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}allyl)acetamide. A sesquisuccinate complex was prepared by the reaction of the above acetamide with succinic acid in acetone solution

IC ICM A61K031-517
INCL 514266210; 544284000
CC 63-6 (Pharmaceuticals)

L47 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:509449 CAPLUS
DOCUMENT NUMBER: 143:193832
TITLE: Process Enabling and the Scale-Up of 6β-(Hydroxymethyl)sulbactam and Its Esters
AUTHOR(S): Norris, Timothy; **Ripin, David H. Brown**; Ahlijanian, Paul; Andresen, Brian M.; Barrila, Mark T.; Colon-Cruz, Roberto; Couturier, Michel; Hawkins, Joel M.; Loubkina, Ioulia V.; Rutherford, Jennifer; Stickley, Kurt; **Wei, Lulin**; Vollinga, Roel; de Pater, Robert; Maas, Peter; de Lang, Ben; Callant, Dominique; Konings, Jeroen; Andrien, Jean; Versleijen, Jos; Hulshof, Jos; Daia, Elena; Johnson, Natalka; Sung, David W. L.
CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research Division, Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Organic Process Research & Development (2005), 9(4), 432-439
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



IV

AB The optimization of the synthesis of 6β-(hydroxymethyl)sulbactam I is described. The primary challenge in this synthesis is the installation of the 6β-hydroxymethyl group with the proper stereochem. Engineering challenges associated with the addition of gaseous formaldehyde to a Grignard reagent at low temperature and a number of approaches to achieving the appropriate β-stereochem. are presented. The first step consisted of converting acid II (R = H) to the benzyl ester II (R = CH2Ph) (III). III was then reacted with MeMgCl, HCHO, AcOH, and H3PO4 to give the 6β-hydroxymethyl-6α-bromo compound along with the 6α-hydroxymethyl-6β-bromo and 6-bromo derivs. The desired 6β-hydroxymethyl-6α-bromo compound, with its impurities, was then hydrogenated to give I. I was then converted to its sodium salt and used in the large scale preparation of two prodrugs, e.g. thiaazabicyclo[3.2.0]heptanecarboxylate IV.

CC 26-5 (Biomolecules and Their Synthetic Analogs)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:470669 CAPLUS

DOCUMENT NUMBER: 143:155246

TITLE: Evaluation of Kilogram-Scale Sonagashira, Suzuki, and Heck Coupling Routes to Oncology Candidate CP-724,714

AUTHOR(S): **Ripin, David H. Brown**; Bourassa, Dennis E.; Brandt, Thomas; Castaldi, Michael J.; Frost, Heather N.; Hawkins, Joel; Johnson, Phillip J.; Massett, Stephen S.; Neumann, Karin; Phillips, James; Raggon, Jeffery W.; Rose, Peter R.; Rutherford, Jennifer L.; Sitter, Barbara; Stewart, A. Morgan, III; **Vetelino, Michael G.**; **Wei, Lulin**

CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research Division, Pfizer Inc., Groton, CT, 06340, USA

SOURCE: Organic Process Research & Development (2005), 9(4), 440-450
CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis of the anticancer compound 2-methoxy-N-(3-{4-[3-methyl-4-(6-methylpyridin-3-yloxy)phenylamino]quinazolin-6-yl}-E-allyl)acetamide (CP-724,714) on multikilogram scale using several different synthetic routes is described. Application of the Sonogashira, Suzuki, and Heck couplings to this synthesis was investigated to identify a safe, environmentally friendly, and robust process for the production of this drug candidate. A convergent and selective synthesis of the candidate was identified which utilizes a Heck coupling of a protected allylamine to install the critical olefin.
CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)
Section cross-reference(s): 28, 63
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1059351 CAPLUS
DOCUMENT NUMBER: 142:23266
TITLE: Process for the preparation of 1,5-naphthyridine-3-carboxamides by direct ester amidation
INVENTOR(S): Karrick, Gregory Lee; **Ripin, David Harold Brown; Wei, Lulin**
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106334	A2	20041209	WO 2004-IB1715	20040517
WO 2004106334	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005038065	A1	20050217	US 2004-856161	20040528

PRIORITY APPLN. INFO.: US 2003-473731P P 20030528
OTHER SOURCE(S): CASREACT 142:23266; MARPAT 142:23266
GI



I

AB Title compds. I (X = H, halo, alkyl, OH, alkoxy, etc.; Y = alkyl, substituted alkyl, etc.) are prepared by heating the corresponding 1,5-naphthyridine-3-carboxylic acid ester with a primary amine in a polar solvent such as DMF or dimethylsulfoxide. Thus, heating 6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic acid Et ester with benzylamine in DMSO at 105-110° for 2-6 h gave, after filtration and crystallization, 67.5% N-benzyl-6-ethoxy-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide.
IC ICM C07D471-00
CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

L47 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:872792 CAPLUS
DOCUMENT NUMBER: 141:366242
TITLE: A processes for preparation of antitumor [(aminoquinazolinyl)allyl]acetamide derivatives from iodo(amino)quinazoline derivative
INVENTOR(S): **Ripin, David Harold Brown; Vetelino, Michael Girard; Wei, Lulin**
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004089934	A1	20041021	WO 2004-IB1069		20040329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2521348	AA	20041021	CA 2004-2521348		20040329
EP 1615910	A1	20060118	EP 2004-724080		20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
US 2005026940	A1	20050203	US 2004-821906		20040409
PRIORITY APPLN. INFO.:			US 2003-461632P	P	20030409
			US 2003-516860P	P	20031103
			WO 2004-IB1069	W	20040329

OTHER SOURCE(S): MARPAT 141:366242
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a processes for preparing (phenylamino)quinazoline

derivs. of formula I [wherein: X is [CH(alkyl)]1-3, (CH2)1-3, or [C(CH2OH)(alkyl)]1-3, etc.; R1, R4, and R5 are independently selected from H or alkyl; R2 is 1-5 substituents; R3 is 0-3 substituents selected from halogen, OH, alkyl, or CF3, etc.; R6 and R7 are independently selected from the group consisting of [C(H/alkyl/CH2OH)(H/alkyl/CH2OH)]1-3-O-alkyl and alkoxy, etc.], useful as antitumor agents (no biol. data). For instance, [(aminoquinazolinyl)allyl]acetamide derivative II [R8 = C(O)CH2OMe] was prepared via aminoalkenylation of iodo(amino)quinazoline derivative III by di-tert-Bu allylamine-N,N-dicarboxylate (example 3, 80% yield) and subsequent amidation of the obtained [(aminoquinazolinyl)allyl]amine derivative II (R8 = H) by methoxyacetyl chloride (example 6, 90-94% yield).

IC ICM C07D401-12

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 45

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:973347 CAPLUS

DOCUMENT NUMBER: 140:76686

TITLE: 2-Methyltetrahydrofuran as an alternative to dichloromethane in 2-phase reactions

AUTHOR(S): **Ripin, David H. Brown; Vetelino, Michael**

CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research Division, Pfizer Inc., Groton, CT, 06340, USA

SOURCE: Synlett (2003), (15), 2353
CODEN: SYNLES; ISSN: 0936-5214

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:76686

AB 2-Methyltetrahydrofuran (MTHF) proved to be a superior solvent to CH2Cl2 in some 2-phase reactions from process and environmental perspectives.

CC 21-2 (General Organic Chemistry)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:767339 CAPLUS

DOCUMENT NUMBER: 140:4999

TITLE: Safety vs Efficiency in the Development of a High-Energy Compound

AUTHOR(S): Ruggeri, Sally Gut; Bill, David R.; Bourassa, Dennis E.; Castaldi, Michael J.; Houck, Tim L.; **Ripin, David H. Brown; Wei, Lulin**; Weston, Neil

CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research Division, Pfizer Inc., Groton, CT, 06340, USA

SOURCE: Organic Process Research & Development (2003), 7(6), 1043-1047
CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:4999

AB A scalable route to 5-(2-carboxy-pyridin-2-yloxy)-benz[1,2,5]oxadiazole (3) is demonstrated. The synthesis was designed to minimize potential safety issues with a previously practiced route and, in particular, to

avoid the handling of 5-hydroxybenzofurazan, which was found to decompose with a large energy release at relatively low temps. The new route builds the benzofurazan moiety onto a nicotinonitrile core to avoid high-energy intermediates with low onset temps. of decomposition

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 63

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L47 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:761612 CAPLUS
DOCUMENT NUMBER: 139:397159
TITLE: Synthesis and Purification of 6-Ethoxy-4-oxo-1,4-dihydro-[1,5]naphthyridine-3-carboxylic Acid Benzylamide
AUTHOR(S): Beaudin, Justin; Bourassa, Dennis E.; Bowles, Paul; Castaldi, Michael J.; Clay, Ronald; Couturier, Michel A.; Karrick, Gregory; Makowski, Teresa W.; McDermott, Ruth E.; Meltz, Clifford N.; Meltz, Morgan; Phillips, James E.; Ragan, John A.; **Ripin, David H.** **Brown**; Singer, Robert A.; Tucker, John L.; **Wei, Lulin**
CORPORATE SOURCE: Chemical Research and Development, Pfizer Global Research Division, Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Organic Process Research & Development (2003), 7(6), 873-878
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:397159
GI



I

AB The synthesis of 6-ethoxy-4-oxo-1,4-dihydro-[1,5]naphthyridine-3-carboxylic acid benzylamide (I) on multikilogram scale is described. The major challenge for the synthesis of this quinolone GABA partial agonist was in the isolation of product of acceptable purity for clin. studies due to the insoly. of this compound Also described are efforts to circumvent a high-temperature cyclization required for the synthesis of the quinolone ring system.

CC 45-4 (Industrial Organic Chemicals, Leather, Fats, and Waxes)
Section cross-reference(s): 63

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Search history

Truong 10/821906 01/20/2006

```
=> d his full

     (FILE 'HOME' ENTERED AT 13:53:08 ON 20 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 13:53:21 ON 20 JAN 2006
L1             STRUCTURE UPLOADED
L2           0 SEA SSS SAM L1

     FILE 'STNGUIDE' ENTERED AT 13:54:26 ON 20 JAN 2006

     FILE 'REGISTRY' ENTERED AT 13:57:31 ON 20 JAN 2006
L3             STRUCTURE UPLOADED
L4           0 SEA SSS SAM L3

     FILE 'STNGUIDE' ENTERED AT 14:00:54 ON 20 JAN 2006

     FILE 'REGISTRY' ENTERED AT 14:03:33 ON 20 JAN 2006
L5             STRUCTURE UPLOADED
L6           0 SEA SSS SAM L5

     FILE 'CASREACT' ENTERED AT 14:04:55 ON 20 JAN 2006
L7             STRUCTURE UPLOADED
L8           0 SEA SSS SAM L7 (     0 REACTIONS)

     FILE 'STNGUIDE' ENTERED AT 14:05:36 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 14:06:22 ON 20 JAN 2006
               E US2004-821906/APPS
L9           1 SEA ABB=ON  PLU=ON  US2004-821906/AP
               SAVE TEMP L9 TRU906APP/A
               SEL RN

     FILE 'REGISTRY' ENTERED AT 14:06:59 ON 20 JAN 2006
L10         14 SEA ABB=ON  PLU=ON  (106-95-6/BI OR 115269-99-3/BI OR 383430-52
               -2/BI OR 383432-38-0/BI OR 383432-65-3/BI OR 383433-12-3/BI OR
               383433-57-6/BI OR 38870-89-2/BI OR 486393-59-3/BI OR 51779-32-9
               /BI OR 537705-08-1/BI OR 537705-10-5/BI OR 778599-38-5/BI OR
               778599-39-6/BI)
               D SCA

     FILE 'CAPLUS' ENTERED AT 14:08:59 ON 20 JAN 2006
               D SCA L9

     FILE 'REGISTRY' ENTERED AT 14:13:19 ON 20 JAN 2006
L11            STRUCTURE UPLOADED
L12         16 SEA SSS SAM L11
               D SCA

     FILE 'CAPLUS' ENTERED AT 14:14:38 ON 20 JAN 2006
L13          4 SEA ABB=ON  PLU=ON  L12

     FILE 'CASREACT' ENTERED AT 14:15:43 ON 20 JAN 2006
L*** DEL     0 S L11 SAM SSS

     FILE 'REGISTRY' ENTERED AT 14:16:23 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 14:17:12 ON 20 JAN 2006
L14          0 SEA ABB=ON  PLU=ON  L13 AND L9
```

```
     FILE 'REGISTRY' ENTERED AT 14:17:37 ON 20 JAN 2006
                D SCA L10
L15          355 SEA SSS FUL L11

     FILE 'CAPLUS' ENTERED AT 14:18:28 ON 20 JAN 2006
L16           19 SEA ABB=ON  PLU=ON  L15

     FILE 'REGISTRY' ENTERED AT 14:19:09 ON 20 JAN 2006
                SAVE TEMP L15 TRU906STRD/A

     FILE 'STNGUIDE' ENTERED AT 14:28:10 ON 20 JAN 2006

     FILE 'REGISTRY' ENTERED AT 14:29:15 ON 20 JAN 2006
L17            0 SEA SUB=L15 SSS SAM L3
L18            0 SEA SUB=L15 SSS FUL L3
                SAVE TEMP L18 TRU906STRB/A

     FILE 'CASREACT' ENTERED AT 14:31:52 ON 20 JAN 2006
L19            0 SEA ABB=ON  PLU=ON  L15/PRO

     FILE 'STNGUIDE' ENTERED AT 14:32:47 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 14:34:02 ON 20 JAN 2006
L20            1 SEA ABB=ON  PLU=ON  L16 AND L9
L21           16 SEA ABB=ON  PLU=ON  L15/PREP

     FILE 'STNGUIDE' ENTERED AT 14:35:43 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 14:43:13 ON 20 JAN 2006
                SEL RN L21

     FILE 'REGISTRY' ENTERED AT 14:46:25 ON 20 JAN 2006
                DELETE SELECT

     FILE 'CAPLUS' ENTERED AT 14:46:54 ON 20 JAN 2006
                SEL RN L21

     FILE 'REGISTRY' ENTERED AT 14:47:04 ON 20 JAN 2006
L22          999 SEA ABB=ON  PLU=ON  (383432-38-0/BI OR 98556-31-1/BI OR
                383430-52-2/BI OR 537705-06-9/BI OR 110-91-8/BI OR 137632-09-8/
                BI OR 2450-71-7/BI OR 383432-27-7/BI OR 383433-14-5/BI OR
                383434-29-5/BI OR 383434-54-6/BI OR 38870-89-2/BI OR 383430-46-
                4/BI OR 383430-82-8/BI OR 383432-25-5/BI OR 383432-65-3/BI OR
                383433-12-3/BI OR 383433-57-6/BI OR 537705-07-0/BI OR 537705-08
                -1/BI OR 537705-10-5/BI OR 202197-26-0/BI OR 230955-75-6/BI OR
                287192-97-6/BI OR 287193-30-0/BI OR 350-30-1/BI OR 383430-47-5/
                BI OR 383430-49-7/BI OR 383430-50-0/BI OR 383430-51-1/BI OR
                383430-53-3/BI OR 383430-54-4/BI OR 383430-55-5/BI OR 383430-69
                -1/BI OR 383430-73-7/BI OR 383430-77-1/BI OR 383431-07-0/BI OR
                383431-08-1/BI OR 383431-09-2/BI OR 383431-59-2/BI OR 383431-72
                -9/BI OR 383431-80-9/BI OR 383432-02-8/BI OR 383432-03-9/BI OR
                383432-04-0/BI OR 383432-26-6/BI OR 383432-58-4/BI OR 383432-63
                -1/BI OR 383432-72-2/BI OR 383433-03-2/BI OR 383433-08-7/BI OR
                383433-40-7/BI OR 383433-81-6/BI OR 383434-51-3/BI OR 383434-53
                -5/BI OR 383434-56-8/BI OR 383434-57-9/BI OR 537705-05-8/BI OR
                7458-03-9/BI OR 79463-77-7/BI OR 92136-39-5/BI OR 106-95-6/BI
                OR 1121-78-4/BI OR 115269-99-3/BI OR 16064-08-7/BI OR 178918-29
                -1/BI OR 179687-79-7/BI OR 179688-52-9/BI OR 179688-53-0/BI OR
                202197-31-7/BI OR 204513-31-5/BI OR 31839-20-0/BI OR 31839-21-1
```

```
              /BI OR 3277-47-2/BI OR 3473-63-0/BI OR 383430-48-6/BI OR
              383430-56-6/BI OR 383430-57-7/BI OR 383430-58-8/BI OR 383430-59
              -9/BI OR 383430-60-2/BI OR 383430-61-3/BI OR 383430-62-4/BI OR
              383430-63-5/BI OR 383430-64-6/BI OR 383430-65-7/BI OR 383430-66
              -8/BI OR 383430-67-9/BI OR 383430-68-0/BI OR 383430-70-4/BI OR
              383430-71-5/BI OR 383430-72-6/BI OR 383430-74-8/BI OR 383430-75
              -9/BI OR 383430-76-0/BI OR 383430-78-2/BI OR 383430-79-3/BI OR
              383430-80-6/BI OR 383430-81-7/BI OR 383430-83-9/BI OR 383430-84
              -0
              DELETE SELECT

     FILE 'CAPLUS' ENTERED AT 14:48:55 ON 20 JAN 2006
              D COST
              SEL RN L21 16

     FILE 'REGISTRY' ENTERED AT 14:49:54 ON 20 JAN 2006
L23           500 SEA ABB=ON  PLU=ON  (102520-97-8/BI OR 108-95-2/BI OR 109608-77
              -7/BI OR 110-91-8/BI OR 120157-98-4/BI OR 123-38-6/BI OR
              124-68-5/BI OR 124400-52-8/BI OR 134575-17-0/BI OR 139-59-3/BI
              OR 160127-75-3/BI OR 160172-20-3/BI OR 16064-08-7/BI OR
              171178-48-6/BI OR 171349-95-4/BI OR 17823-94-8/BI OR 18994-77-9
              /BI OR 191284-80-7/BI OR 199538-99-3/BI OR 20734-46-7/BI OR
              2450-71-7/BI OR 255864-58-5/BI OR 26807-73-8/BI OR 275387-76-3/
              BI OR 275387-83-2/BI OR 287188-70-9/BI OR 287188-71-0/BI OR
              287188-72-1/BI OR 287188-73-2/BI OR 287188-74-3/BI OR 287188-75
              -4/BI OR 287188-76-5/BI OR 287188-77-6/BI OR 287188-78-7/BI OR
              287188-79-8/BI OR 287188-80-1/BI OR 287188-82-3/BI OR 287188-83
              -4/BI OR 287188-84-5/BI OR 287188-85-6/BI OR 287188-86-7/BI OR
              287188-87-8/BI OR 287188-88-9/BI OR 287188-89-0/BI OR 287188-90
              -3/BI OR 287188-91-4/BI OR 287188-92-5/BI OR 287188-93-6/BI OR
              287188-94-7/BI OR 287188-95-8/BI OR 287188-96-9/BI OR 287188-97
              -0/BI OR 287188-98-1/BI OR 287188-99-2/BI OR 287189-00-8/BI OR
              287189-01-9/BI OR 287189-02-0/BI OR 287189-03-1/BI OR 287189-04
              -2/BI OR 287189-05-3/BI OR 287189-06-4/BI OR 287189-07-5/BI OR
              287189-08-6/BI OR 287189-09-7/BI OR 287189-10-0/BI OR 287189-11
              -1/BI OR 287189-12-2/BI OR 287189-13-3/BI OR 287189-14-4/BI OR
              287189-15-5/BI OR 287189-16-6/BI OR 287189-17-7/BI OR 287189-18
              -8/BI OR 287189-19-9/BI OR 287189-21-3/BI OR 287189-23-5/BI OR
              287189-24-6/BI OR 287189-25-7/BI OR 287189-26-8/BI OR 287189-27
              -9/BI OR 287189-28-0/BI OR 287189-29-1/BI OR 287189-30-4/BI OR
              287189-31-5/BI OR 287189-32-6/BI OR 287189-33-7/BI OR 287189-34
              -8/BI OR 287189-35-9/BI OR 287189-36-0/BI OR 287189-37-1/BI OR
              287189-38-2/BI OR 287189-39-3/BI OR 287189-40-6/BI OR 287189-41
              -7/BI OR 287189-42-8/BI OR 287189-43-9/BI OR 287189-44-0/BI OR
              287189-45-1/BI OR 287189-46-2/BI OR 287189-47-3/BI OR 287189-
L24          1400 SEA ABB=ON  PLU=ON  L22 OR L23
L25          1054 SEA ABB=ON  PLU=ON  L24 NOT L15

     FILE 'STNGUIDE' ENTERED AT 14:53:39 ON 20 JAN 2006

     FILE 'REGISTRY' ENTERED AT 14:54:19 ON 20 JAN 2006
              E QUINAZOLINE/CN
L26             1 SEA ABB=ON  PLU=ON  QUINAZOLINE/CN
              D RSD
              D SCA
L27         88037 SEA ABB=ON  PLU=ON  591.100.47/RID
L28           780 SEA ABB=ON  PLU=ON  L25 AND L27

     FILE 'CAPLUS' ENTERED AT 14:56:14 ON 20 JAN 2006
```

```
     FILE 'REGISTRY' ENTERED AT 14:56:36 ON 20 JAN 2006
L29        1126 SEA ABB=ON  PLU=ON  L24 AND L27

     FILE 'CAPLUS' ENTERED AT 14:56:55 ON 20 JAN 2006
L30         185 SEA ABB=ON  PLU=ON  L29 (L) (RACT OR RCT OR RGT)/RL
L31          16 SEA ABB=ON  PLU=ON  L30 AND L21

     FILE 'REGISTRY' ENTERED AT 14:59:14 ON 20 JAN 2006
L32        1082 SEA ABB=ON  PLU=ON  L29 AND C6/ES
L33         449 SEA ABB=ON  PLU=ON  L32 AND A7/PG
L34         320 SEA ABB=ON  PLU=ON  L33 NOT L15

     FILE 'STNGUIDE' ENTERED AT 15:06:01 ON 20 JAN 2006

     FILE 'REGISTRY' ENTERED AT 15:16:24 ON 20 JAN 2006
L35               STRUCTURE UPLOADED
L36           1 SEA SSS SAM L35
                  D SCA
L37           2 SEA SUB=L24 SSS SAM L35
                  D SCA
L38          49 SEA SUB=L24 SSS FUL L35
                  SAVE TEMP TRU906STRRCT/A L38

     FILE 'CAPLUS' ENTERED AT 15:18:50 ON 20 JAN 2006
L39          27 SEA ABB=ON  PLU=ON  L38 (L) (RCT OR RGT OR RACT)/RL
L40          13 SEA ABB=ON  PLU=ON  L39 AND L21

     FILE 'REGISTRY' ENTERED AT 15:20:25 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 15:23:57 ON 20 JAN 2006
               D IBIB ABS HITIND HITSTR L40 1

     FILE 'REGISTRY' ENTERED AT 15:27:48 ON 20 JAN 2006
               D STAT QUE L18

     FILE 'CASREACT' ENTERED AT 15:29:37 ON 20 JAN 2006
               D STAT QUE L19

     FILE 'STNGUIDE' ENTERED AT 15:31:26 ON 20 JAN 2006

     FILE 'REGISTRY' ENTERED AT 15:33:28 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 15:33:48 ON 20 JAN 2006
               D STAT QUE L40
               D IBIB ABS HITIND HITSTR L40 1-13

     FILE 'BEILSTEIN' ENTERED AT 15:36:26 ON 20 JAN 2006
L41            0 SEA SSS FUL L3

     FILE 'BEILSTEIN' ENTERED AT 15:37:15 ON 20 JAN 2006
               D STAT QUE L41

     FILE 'MARPAT' ENTERED AT 15:40:05 ON 20 JAN 2006

     FILE 'CAPLUS' ENTERED AT 16:10:57 ON 20 JAN 2006
L42          51 SEA ABB=ON  PLU=ON  RIPIN D?/AU
L43          19 SEA ABB=ON  PLU=ON  VETELINO M?/AU
L44        2406 SEA ABB=ON  PLU=ON  WEI L?/AU
```

```
L45             2 SEA ABB=ON  PLU=ON  L42 AND L43 AND L44
                  D SCA TI
L46             8 SEA ABB=ON  PLU=ON  (L42 AND (L43 OR L44)) OR (L43 AND L44)

     FILE 'CAPLUS' ENTERED AT 16:12:47 ON 20 JAN 2006
                  D QUE L45
                  D QUE L46
L47             8 SEA ABB=ON  PLU=ON  L45 OR L46
                  D IBIB ABS HITIND L47 1-8


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   18 JAN 2006  HIGHEST RN 872163-75-2
     DICTIONARY FILE UPDATES:  18 JAN 2006  HIGHEST RN 872163-75-2

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE STNGUIDE
     FILE CONTAINS CURRENT INFORMATION.
     LAST RELOADED: Jan 13, 2006 (20060113/UP).

     FILE CASREACT
     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.

     FILE CONTENT:1840 - 15 Jan 2006 VOL 144 ISS 3

     New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

****
*
* CASREACT now has more than 10 million reactions
*
****

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CAPLUS

FILE COVERS 1907 - 20 Jan 2006 VOL 144 ISS 5
FILE LAST UPDATED: 19 Jan 2006 (20060119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 17, 2006

FILE COVERS 1771 TO 2005.
FILE CONTAINS 9,428,406 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *

* FOR PRICE INFORMATION SEE HELP COST *
****

NEW

*** PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.**

*** NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.**

FILE MARPAT
FILE CONTENT: 1969-PRESENT (VOL 144 ISS 3 (20060116/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1969-1987

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6958359 25 OCT 2005
DE 1020040544 27 OCT 2005
EP 1589024 26 OCT 2005
JP 2005320486 27 OCT 2005
WO 2005110983 24 NOV 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.